Curriculum Vitae för Parkinsonfondens Vetenskapskommitté

Curriculum Vitae

Prof. Per Lars Anders ODIN
Auf dem Hohen Ufer 65b
D-28759 Bremen
Mobile +49(0)1752048124
e-mail: per.odin@med.lu.se
Nationality: Swedish
Born: 10th. July, 1957 in Uppsala
Family: Married to Katja Odin, 3 children.

Education:

9 years of compulsory school, Örjansskolan, Halmstad 1965-1973
3 years of college, Natural Science Program, Halmstad 1973-1976
Medical studies, University of Uppsala 1976-1982
"Medicine Kandidat" Degree, University of Uppsala 19.06.78
"Läkarexamen" Degree, University of Uppsala 18.01.82

PhD research, Dept. of Medical and Physiological Chemistry, Uppsala Univ. 1982-1987
(Tutor: Professor Björn Öbrink).
Doctor of Medical Sciences, University of Uppsala 23.05.87
Thesis: "Chemical, immunochemical and immunohistochemical **characterization of the cell adhesion molecule CellCAM 105"**

Employment/Exams **(employment details separately below)**:

Clinical duties and research 1987-1996
Department of Neurology, Lund University
(Research area: Neurotransplantation, Neuroprotection)
(Heads of Department: Prof. Olle Lindvall and Prof. Anders Björklund)
Certified physician ("legitimerad läkare"), University Hospital, Lund 01.11.89
Neurology Specialist, University Hospital, Lund 16.11.93
Associate Professor ("Docent") of Neurology, Lund University 08.09.94
Specialist, Consultant ("Bitr. Överläkare"), Dept. of Neurology, Lund 1994-1996
Lecturer ("Universitetslektor" (50%)), Lund University 1995-1996

Consultant ("Oberarzt"), Dept. of Neurology, The Hannover Medical School 1996-1999
(Head of Department: Prof. Reinhard Dengler)
Associate Professor ("Dr. med. habil."), The Hannover Medical School 15.01.97
Extraordinary Professor, ("Außerplanmäßiger Professor"), 14.10.98
The Hannover Medical School

Extraordinary Professor, ("Außerplanmäßiger Professor"), 14.10.98
The Hannover Medical School

National Coordinator of Kompetenznetz-Parkinson and 1999-2001
Consultant at the Dept. of Neurology, Philipps-University, Marburg
(Head of Department: Prof. Wolfgang Oertel)

Head of the Dept. of Neurology, Central Hospital, Bremerhaven 2001-

Professor
2009-
Department of Neurology, Lund University

Scientific publications: 143 (including 75 original publications and 67 bookchapters/reviews)
H-index: 29 **Average Citations per item:** 18.11
Scientific lectures and posters: **>200**

Clinical positions
University Hospital, Lund Internship ("AT-läkare") 01.02.88 - 31.10.89
University Hospital, Lund Resident physician ("FV-läkare") 01.11.89 - 30.11.93
University Hospital, Lund Specialist ("avdelningsläkare")/
Dept. of Neurology Consultant ("bitr. överläkare") 01.12.93 - 30.09.96
The Hannover Medical School Consultant
("Oberassistent") 01.10.96 – 31.10.99
Dept. of Neurology
Philipps-University Marburg Consultant, Coordinator
of 01.11.99 – 31.03.01
Dept. of Neurology Kompetenznetz-Parkinson
Central Hospital, Bremerhaven Head of Dept 01.04.01 -
Dept. of Neurology

Research positions
University of Uppsala PhD-Student "Doktorand" 01.07.78 - 31.07.78
Dept. of Med. and Physiol. PhD-Student "Doktorand" (Tutor) 01.02.82 - 28.02.83
Chemistry PhD-Student "Doktorand"
(MFR*) 01.03.83 - 28.02.87
PhD-Student
"Doktorand" 01.03.87 - 31.07.87
Lund University Post-doc. "Forskarassistent"(MFR*) 01.09.91 - 30.11.91
Dept. of Neurology Post-doc.
"Forskarassistent" 01.07.92 - 01.09.92
Post-doc.
"Forskarassistent"(MFR*) 01.09.92 - 30.11.92
Post-doc.
"Forskarassistent" 01.12.92 - 31.12.92
Post-doc.
"Forskarassistent" 01.05.93 - 30.06.93
Post-doc.
"Forskarassistent"(MFR*) 01.08.93 - 31.10.93
Post-doc.
"Forskarassistent" 01.11.93 - 09.01.94
Post-doc.
"Forskarassistent" 28.02.94 - 31.03.94
Post-doc.
"Forskarassistent" 15.04.94 - 30.04.94

"Forskarassistent" 28.02.94 - 31.03.94
Post-doc.
"Forskarassistent" 15.04.94 - 30.04.94
Post-doc.
"Forskarassistent" 16.05.94 - 16.06.94
Post-doc.
"Forskarassistent" 01.07.94 - 15.09.94
Post-doc.
"Forskarassistent" 17.10.94 - 27.11.94
Post-doc.
"Forskarassistent" 19.12.94 - 08.01.95
Lund University Senior research
fellow 06.02.95 - 02.04.95
Dept. of Neurology
("Universitetslektor") 01.05.95 - 07.05.95

05.06.95 - 18.06.95

14.08.95 - 01.10.95

23.10.95 - 03.12.95

12.02.96 - 10.03.96

14.04.96 - 31.08.96
Lund
University Professor 01.
09.09 - 31.07.13
Dept. of Neurology ("Adj. Professor")
Lund University Professor of Clinical Neuroscience 01.08.13 –
Dept. of Neurology

Tutor for doctoral students, thesis finished*:
N. Schimke, 2003
A. Brederlau, 2003
A. van den Hoogen, 2005
H. Honig, 2011
T. Fox, 2013
*A German medical dissertation is normally based on about one year of full-time research and is usually equivalent to one scientific publication.

Leading posts in academic organizations
Chairman, Scientific Committee, Swedish National Guidelines for PD (Socialstyrelsen), 2014-
Chairman, "Swedish Movement Disorder Society, SWEMODIS", 2002-2014
Chairman, "Scandinavian Movement Disorder Society, ScandMODIS", 2008-
Chairman, SWEPAR (Swedish Parkinson Research Network), 2010-
Member of the executive committee of Movement Disorder Society, European Section, 2011-
Member of the CSPC (Congress Scientific Program Committee) of MDS, 2009-
Member of the board (treasurer) of Competence Network Parkinsons disease, CNP, 2010-

Clinical trials

I have been actively involved as principal investigator in the clinical studies listed below, was national co-ordinating investigator for the high-dose cabergoline study and leading German investigator (LKP) for the nasal apomorphine study (20102D05):

Apomorphin Inj. Lund
University 1993-95
Sponsor: Novo Nordisk

Riluzol The Hannover Medical
School Phase III 1997-99

Riluzol The Hannover Medical School Phase III 1997-99
Sponsor: Aventis

High dose Cabergolin University of Marburg Phase III 1998-2001
Sponsor: Pharmacia

E2007-204 Central hospital, Bremerhaven Phase IIb 2004-5
Sponsor: Eisai/i3

E2007-205 Central hospital, Bremerhaven Phase IIb 2004-5
Sponsor: Eisai/i3

PDT 301, DAT-Scan in PD Central hospital, Bremerhaven Phase III 2004-6
+Dementia
Sponsor: GE Health

SP790/791, Rotigotine in RLS Central hospital, Bremerhaven Phase III 2005-7
Sponsor: Schwarz Pharma

E2007-E044-301 Central hospital, Bremerhaven Phase III 2006-7
Sponsor: Eisai/Quintiles

20102D05 Apomorphine Central hospital, Bremerhaven Phase III 2006-7
Nasal
Sponsor: MDS/Britannia

E2007-G000-303 Central hospital, Bremerhaven Phase III 2007
Sponsor: Eisai/Quintiles

248.596 Pramipexole in Central hospital, Bremerhaven Phase III 2007
Parkinson+Depression
Sponsor: Boehringer-Ingelheim

248.524 Pramipexole ER Central hospital, Bremerhaven Phase III 2007
Sponsor: Boehringer-Ingelheim

S308.3.004 Rubens Study Central hospital, Bremerhaven Phase III 2008
Sponsor: Solvay Pharma

SP882 Neupro perioperativ Central hospital, Bremerhaven Phase III 2008
Sponsor: Schwarz Pharma

S187.3.001 Duodopa Central hospital, Bremerhaven Phase III 2008-
Sponsor: Solvay Pharma

S187.3.004 Duodopa Central hospital, Bremerhaven Phase III 2008-
Sponsor: Solvay Pharma

III 2008-
Sponsor: Solvay Pharma

VR040/2/008 Apomorphine Central hospital, Bremerhaven Phase III 2008
Inhalation
Sponsor: Vectura

S187.1.001 Duodopa Central hospital, Bremerhaven Phase I 2010
Sponsor: Solvay Pharma

PYM50028 Cogane Central hospital, Bremerhaven Phase II 2011
Sponsor: Phytopharm

PO4938 Predeladent Central hospital, Bremerhaven Phase III 2011
Sponsor: Schering

PO5664 Predeladent Central hospital, Bremerhaven Phase III 2011
Sponsor: Schering

NIC-PD Central Hospital, Bremerhaven Phase III 2012
Sponsor: German Parkinson Study Group

Toledo Apomorphine Central Hospital, Bremerhaven Phase III 2014
Sponsor: Stada

sNN0031-004 PDGF Central Hospital, Bremerhaven Phase II 2014
Sponsor: EU, Newron

KW-6002 Istradefylline Central Hospital Bremerhaven Phase III 2014
Sponsor: Kyowa

10 best original publications:

Pietz K., **Odin P.,** Funa K. and Lindvall O. (1996) Protective Effect of PlateletDerived Growth Factor protects against 6-hydroxydopamine-induced lesion of rat dopaminergic neurons in culture. *Neurosci Lett,* **204**, 101-104.

Wenning G.K., **Odin P.,** Morrish P., Rehncrona S., Widner H., Brundin P., Rothwell J.C., Brown R., Gustavii B., Hagell, P., Jahanshahi M., Sawle G., Björklund A., Brooks J.D., Marsden C.D., Quinn N.P. and Lindvall O. (1997) Short- and Long-term Survival and Function of Unilateral Intrastriatal Dopaminergic Grafts in Parkinson´s Disease. *Ann Neurol,* **42**, 95-107.

Pietz K., Hagell P. and **Odin P.** (1998) Subcutaneous apomorphine in late stage Parkinson´s disease: a long term follow up. *J Neurol Neurosurg Psychiatry,* **65**, 709-716.

Odin P., Oehlwein C., Storch A., Polzer U., Werner G., Renner R., Shing M., Ludolph A., Schüler P. (2006) Efficacy and safety of high-dose cabergoline in Parkinson´s disease. *Acta Neurol Scand*, 113, 18-24.

Eggert K., Schrader C., Hahn M., Stamelou M., Rüssmann A., Dengler R., Oertel W., **Odin P**. (2008) Continuous jejunal levodopa infusion in patients with advanced Parkinson´s disease: Practical aspects and outcome of motor and non-motor complications. *Clin Neuropharmacol*, 31, 151-66.

Brüggemann N., **Odin P**., Grünewald A., Tadic V., Hagenah J., Seidel G., Lohmann K., Klein C., Djarmati A. (2008) Alpha-synuclein duplication is present in sporadic Parkinson disease. *Neurology*, 71, 1294.

Honig H., Antonini A., Martinez-Martin P., Forgacs I., Faye G.C., Fox T., Fox K., Mancini F., Caneci M., **Odin P**., Chaudhuri K.R. (2008) Intrajejunal levodopa infusion in advanced Parkinson's disease: a pilot multicentre study of effects on non-motor symptoms and quality of life. *Mov Disord*, **24**, 1468-74.

Antonini A., **Odin P**., Opiano L., Tomantscheger V., Pacchetti C., Pickut B., Gasser U.E., Calandrella D, Mancini F., Zibetti M., Minafra B., Bertaina I., De Deyn P., Cras C.,

and quality of life. *Mov Disord*, **24**, 1468-74.

Antonini A., **Odin P**., Opiano L., Tomantscheger V., Pacchetti C., Pickut B., Gasser U.E., Calandrella D, Mancini F., Zibetti M., Minafra B., Bertaina I., De Deyn P., Cras C., Wolf E., Spielberger S., Poewe W. (2013) Effect and safety of duodenal infusion in advanced Parkinson´s disease: a retrospective multicenter outcome assessment in patient routine care. *J. Neurol. Transm*. **120**, 1553-8.

Nyholm D., **Odin P**., Johansson A., Chatamra K, Locke C., Freeman S., Dutta S., Othman A.A. (2013) Stable Levodopa Plasma Levels with Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson´s Disease Patients. **AAPS** J. **15**:316-23.

Olanow C.W., Kieburtz K., **Odin P.**, Espay A.J., Standaert D.G., Fernandez H.H., Vanagunas A., Othman A.A., Widnell K.L., Robieson W.Z., Pritchett Y., Chatamra K., Benesh J., Lenz R.A., Antonini A.; LCIG Horizon Study Group. (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. *Lancet Neurol*. **13**, 141-9.

Bremerhaven 13. Aug 2014

Per Odin

Curriculum Vitae Malin Parmar

Name **Malin Pernilla Parmar**
Date of birth: 1973-12-11
Citizenship: Swedish
Telephone, work: + 46 46 222 0620
Mobile phone: + 46 709 823901
E-mail: **Malin.Parmar@med.lu.se**
Web: **Developmental Neurobiology**

Higher education degree
1998 Bachelor of Science, Simon Fraser University, Canada

Doctoral degree
2003 PhD in Medical Sciences, developmental biology.
Medical Faculty, Lund University. Degree awarded 2003-09-26.

Postdoctoral positions
2005-2006 **Postdoc position, financed by Swedish Research Council**
Faculty of Science, Institute of Stem Cell Research
Edinburgh University, Scotland, UK.
2003-2005 ***PostDoc Position***
Faculty of Medicine, Lund University, Sweden

Docent level
2008 Docent in Neurobiology
Medical Faculty Lund University

Specialist Certification
N/A

Specialist Certification
N/A

Current position
Associate professor (Lektor) **at the Department of Experimental Medical Science: Wallenberg Neuroscience Centre and Lund Stem Cell Centre, Medical Faculty, Lund University**

Previous Positions (excl postdoc positions that are listed above)
2012-2014 Senior Researcher.
Faculty of Medicine, Lund University, Sweden
2007-2012 Assistant Professor (Forskarassistent). Fully financed by the Swedish Research Council
Faculty of Medicine, Lund University, Sweden
1999-2003 PhD Position, financed by National network in Neuroscience, SSF. **Faculty of Medicine, Lund University, Sweden**
1998-1999 **Project Student**, Terry Fox Laboratory, University of British Columbia, BC, Canada

Career breaks
Since my Phd was awarded I have had two careers breaks (total 488 days) for parental leave when my children were born (2004 and 2008)
Supervision as main supervsor:
Completed Phd students:
Jenny Nelande: 12/12-2013
Olof Torper: 28/2-2014

Ongoing Phd students:
Ulrich Pfisterer: Booked dissertation date 19/9-2014
Maria Pereira: Registered Jan 1, 2013

Main supervisor Postdocs:
Audrey Dufour 2009-2011
Daniel Wolf 2010-2012
Agnete Kirkeby 2010 - 2013
Shane Grealish 2011 - currently
Shong Lau 2012 - currently
Daniella Rylander 2013 - currently
Andreas Heuer 2013 - currently

National and International awards:
2012 ERC Starting Grant

Other significant activities
2013 – 2016 Board member, "Membership committee", International Society for Stem Cell Research, ISSCR
2014 – Currently: Swedish Parkinson Fundation Scientific Committee
2013-2015: Editorial Board for Experimental Neurology
2009 – 2013 Training and Networking Director for 7th framework EU program NeuroStemcell: responsible for activities and training of PhD students and postdocs within the network, organizing scientific workshops and meeting as well as communication with other EU networks and public.
1999 – Currently: Involved in teaching (PBL tutor, lecturer, examination and course leader) at the medical, biomedical programs and PhD program at Lund University
2008 - Currently: Co-Director of Research School in Stem Cell Biology, LU
2009 – Currently: External expert and writer for the Swedish National Encyclopaedia (NE)

CV Lars Forsgren

CV Lars Forsgren

Lars Forsgren	Professor, överläkare

A. Akademisk och gymnasial utbildning			
Utbildning	Examina	År	Ämnesområde
Forskarutbildning	Dr Med Vet	1990	Neurologi
Specialistutb i neurologi	Special.komp	1984	Neurologi
Epidemiologi statistik 10 p		1988	
Legitimerad läkare		1979	
Läkarutbildning	Läkarexamen	1978	
Psykologi 40 p		1970-71	
Gymnasieutb samhällsvet & naturvetenskaplig linje	Studenten	1970 och 1972 (natur)	
High School USA	High school examen	1967-68	

B. Professionella befattningar	
År	Befattning
2014-	Medlem i forskningsstrategiska nämnden, med.fak, Umeå universitet
2012-	Medlem i vetenskapliga rådet för Stiftelsen Parkinson Research Foundat
2012-	Medlem i strategiska gruppen för biobanksforskning, Umeå universitet
2011-2013	Medlem i en neurobedömargrupp vid Vetenskapsrådet (medicin)
2009-	Medlem i Parkinsonfondens vetenskapliga nämnd
2006-2012	Medlem i Hjärnfondens vetenskapliga nämnd, 2012- ordf för 1/3 grupper
2006-2011	Ordförande i neuroprioriteringsgruppen för ALF i Stockholm (KS/Hudd)
2005-2007	Ordförande i 1 av 2-3 kommittér för fördelning av ALF-medel i Umeå
2004-2007	Ordförande vetenskapskommittén Neurologisk Handikappades Riksförb
2004-	Sveriges representant i World Federation of Neurology
2004-2006	Book review editor Acta Neurologica Scandinavica
2002-2008	Ledamot i Umeå universitets medicinska fakultets forskningsråd
2003-	Member European Brain Council group on epidemiology
2002-	Expertmedlem Medicinska biobanken i Umeå (i kommittén för kardiovaskulära och andra sjukdomar)
2002-	Member Editorial Board Acta Neurologica Scandinavica
1998-2004	Member Editorial Board Epilepsia
1996-	Ledamot i kommitteen för utdelande av Mångbergs pris
1996-	Professor och överläkare i neurologi vid Umeå universitet/sjukhus
1996-2002	Klinikchef vid neurologiska kliniken, Norrlands universitetssjukhus
1996-	Prefekt eller ställföreträdande prefekt vid Institutionen för Farmakologi och Klinisk Neurovetenskap, Umeå universitet.
1998-2002	Ordförande i Nordisk Neurologisk Förening (från 2002 styrelsemedlem)
1995-1998	Ordförande i Svenska Neurologföreningen (styrelsemedlem ytterlig 6 år)
1995-2007	Medlem i vetenskapskommittén Neurologisk Handikappades Riksförb
1994-1997	Committee member of the International League Against Epilepsy's Commission on Epidemiology and Prognosis
1991-1998	Styrelsemedlem i Svenska Epilepsisällskapet
1991	Docent i neurologi vid Umeå universitet
1991-	Corresponding Fellow of the American Academy of Neurology (FAAN)
1989-1996	Sekreterare i Umeå Neurovetenskapliga Sällskap
1986-1991	Biträdande överläkare i neurologi vid Regionsjukhuset i Umeå
1986 (July)	Visiting Research Fellow Dystonia Clinical Research Center, New York (professor Stanley Fahn)
1984-1986	Avdelningsläkare i neurologi vid Regionsjukhuset i Umeå
1982 Febr/March	Visiting Research Fellow Texas Institute of Rehabilitation and Research (professor M Dimitirijevic)
1980-1984	FV-läkare i neurologi vid Regionsjukhuset i Umeå
1978-1980	AT-läkare vid Örnsköldsviks sjukhus

	(professor M Dimitirijevic)
1980-1984	FV-läkare i neurologi vid Regionsjukhuset i Umeå
1978-1980	AT-läkare vid Örnsköldsviks sjukhus

C. Meriter och utmärkelser	
År	Meriter och utmärkelser
2009	Parkinsonförbundets hedersmedalj Utöver vad som nämns ovan har jag bedömt ansökningar för Brittiska och Danska forskningsråden samt FAS. Har också varit sakkunnig på akademiska tjänster, främst professurer, vid samtliga Svenska universitet, samt vid Columbia university, New York.

Curriculum Vitae för Per Svenningsson

Born: Lund, Sweden, December 19, 1968.
Home address: Observatoriegatan 23
SE-113 29 Stockholm
Sweden
Work address: Department of Neurology
Karolinska University Hospital
SE-141 86 Stockholm
and
Department of Clinical Neuroscience
Center for Molecular Medicine L8:01
Karolinska Institutet
SE-171 77 Stockholm
Sweden
Phone: +46 (0)8 51774614/ +46 70 7498522
Fax: +46 (0)8 51774614
e-mail: per.svenningsson@ki.se

Current Position

Professor in Neurology, Dept. of Neurology, Karolinska University Hospital/Dept. of Clinical Neuroscience, Karolinska Institutet.

Education

1990-1996 Medical School, Karolinska Institute, Sweden. Medical Doctor, January 19 1996.
1992-1998 Graduate studies, Dept of Physiology and Pharmacology, Karolinska Institute. PhD October 15, 1998.
1999 Licensed medical doctor, May 21.
2002 Associate Professor ("Docent"), Karolinska Institutet, September 18.
2010 Specialist in Neurology, December 6.

Professional experience

1996-1999 Medical Internship (Surgery, Internal Medicine and Psychiatry wards)/Research, "Forskar-AT", Karolinska University Hospital.
1999-2001 Postdoctoral fellow in Prof. Paul Greengard's Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, USA.
2001-2002 Assistant professor in Prof. Paul Greengard's Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, USA.
2002-2006 Research assistent (VR forskarassistenttjänst), Dept. of Physiology and Pharmacology, Karolinska Institutet, Sweden.
2005-2010 Medical Residency (ST-tjänst) in Neurology, Karolinska University Hospital.
2009-2015 Researcher (VR forskartjänst), Dept. of Clinical Neuroscience, Karolinska Institutet.
2012- Professor in Neurology, Dept. of Neurology, Karolinska University Hospital/Dept. of Clinical Neuroscience, Karolinska Institutet.

Institutet.
2012- Professor in Neurology, Dept. of Neurology, Karolinska University Hospital/Dept. of Clinical Neuroscience, Karolinska Institutet.

Honors and Awards

2006 Opening Plenary Lecture, XIV World Congress on Psychiatric Genetics
2007 NARSAD Young Investigator Award
2008 Werner Lowenthal´s Lecture, Richmond, USA
2008 Researcher position from the Royal Swedish Academy of Sciences
2011, 2012, 2013 Fisher Center Grant Award

Commisions of Trust

2005-2008 Grant reviewer for INSERM/ANR, France
2008- Swedish Movement Disorder Society, elected board member
2009- Swedish Parkinson Fund, scientific reviewing committee
2009 Finnish Medical Research Council, scientific reviewing committee
2010, 2013 Norwegian Medical Research Council, scientific reviewing committee
2010- Scientific coordinator between Karolinska Institutet and Rockefeller University
2010- Member of the Ulf von Euler Lecturer committee, Karolinska Institutet
2011, 2014 Member of the programme committee for the European College of Neuropsychopharmacology (ECNP) meetings in Paris 2011 and Berlin 2014
2012- Parkinson Research Foundation, scientific committee
2013 Swedish Foundation for Strategic Research (SSF), reviewing committee
2013- Member of the Executive Committee for ECNP
2013- Member of SAB for CBD solutions
2014- Member of the Steering Committee of the European Huntington Disease Network

Membership of Editorial Boards of Scientific Journals

2009- J Mol Neuroscience
2012- PLoS ONE
2012- Frontiers in Psychopharmacology
2012- ISRN Neurology

Invited lectures

Over the years, I have been invited to speak at a large number (>50) of congresses, symposia and workshops throughout the world.

Scientific supervision

Main supervision of 9 Ph.D. students (completed PhD), 2004-2014.
Currently main supervision of 5 Ph.D. students.
Supervision of 8 postdocs, 2004-2014.
Currently main supervision of 8 postdocs.

Publications

168 publications with 7001 citations; H-index 48.
8 book chapters

CV Johan Lökk (1951-06-18)

1. Higher education degree(s)
   MD 1976 Authorised MD 1978

1. Higher education degree(s)
MD 1976 Authorised MD 1978

2. Doctoral degree
1991, Karolinska Institutet, ”On the effects of an autonomous daycare unit”

3. Postdoctoral positions
N/A

4. Docent level
1998 Karolinska Institutet, Clinical neuroscience

5. Specialist certification or equivalent
Geriatrics 1983, Internal medicine 1988

6. Present position
Senior consultant, Head physician, Geriatric Dept, Karolinska University Hospital; Professor of Geriatrics at the Department of Neurobiology, Care Sciences and Society, Karolinska Institutet.

7. Previous positions and periods of appointment
2000-2010 Senior lecturer, Karolinska Institutet
1992-2000 Senior consultant, section head of rehabilitation unit, Geriatric Dept, Karolinska University Hospital
1988-1992 Senior consultant, Dalens Hospital, Stockholm
1985-1988 Consultant, Danderyds Hospital, Stockholm
1983-1985 Physician, Stureby Hospital, Stockholm

8. Interruption in research
N/A

9. Supervision
Main supervisor (completed): Mats Nilsson (2008), Sylvia Annerbo (2009), Ahmad Delbari (2011); (Ongoing): Örjan Skogar (2008-), Mohamad Fereshtehnejad(2011-). Co-supervisor: Lena Flodin, Katja Samuelsson, Frida Göthe, David Conradsson, Ingrid Claesson

10. Others
· Accountant of Parkinsonföreningen 1999
· Member of the board of Research and Development at NVS, KI, 2001--
· Member of the Committee for doctoral education (FoUK) at the Department of Neurobiology, Care Sciences and Society, 2002—
· Board member Geriatric Dept, Karolinska University Hospital 2002-
· Board member FoUU-committee, NVS-dept, Karolinska Institutet 2005-
· Board member Swedish Parkinson Foundation 2010-
· Member of Regional Ethical Committee, Karolinska Institutet 2009-

· Board Member Swedish Movement Disorder Society (SWEMODIS) 2012-
· Member of Medical Advisory Boards for Lundbecks, Boehringer-Ingelheim, Pfizer, Ferring

My research is focused on neurodegenerative diseases with special

interest in Parkinson’s disease and currently a project about

Parkinson's disease on how different forms of physical treatment

interest in Parkinson's disease and currently a project about Parkinson's disease on how different forms of physical treatment affect function and psycho-endocrinology. I have also extended the research to epidemiological issues and have a joint program with the University of Teheran and the University of Sabzewar. Moreover, I have cooperation with researchers in Alzheimer´s disease and is currently investigating predictive factors for developing dementia in MCI and SCI patients. I have a total of 28 years in the geriatric field, of which 26 years as consultant or senior, giving me a unique expertise in the field of neurogeriatrics.

CV Anders Johansson, MD, PhD

Silverdalsvägen 31, lgh 1004
191 38 Sollentuna
Sweden
Phone numbers:
office: 0046-8-51773424, mobile: 0046-73-6130611, home: 0046-8-50906369
Email address: anders.c.johansson@karolinska.se

Education and Medical Training

Fellowship / Residency, Department of Neurology 04/01/1998—10/12/2003
University Hospital, Uppsala, Sweden

Internship
08/01/1995—04/30/1997
Arvika Hospital, Arvika, Sweden
Departments of Internal medicine, Surgery, Psychiatry and General Practice

Doctor of Philosophy, Faculty of Medicine 06/13/2009
Department of Neuroscience, Uppsala University, Uppsala, Sweden

University Medical Degree

21/07/1995
Uppsala University, Faculty of Medicine, Uppsala, Sweden

Professional Work History

Consultant Physician, Department of Neurology 05/16/2011—
Karolinska University Hospital
Solna, Stockholm, Sweden

Consultant Physician, Department of Neurology 06/01/2010—05/15/2011
University Hospital, Uppsala, Sweden
Responsabilities: Deep brain stimulation, Dystonia treatment with botulinum toxin, Huntington disease, Parkinson disease

Responsibilities: Deep brain stimulation, Dystonia treatment with botulinum toxin, Huntington disease, Parkinson disease

Neurologist, Department of Neurology 10/14/2003 — 05/31/2010
University Hospital, Uppsala, Sweden

Licensure and Certifications

License to Practice

05/21/1997
Specialist of Neurology

10/13/2003

Professional Memberships

The Movement Disorder Society (MDS)
The Swedish Movement Disorder Society (SWEMODIS))
Uppsala Medical Society
Swedish Medical Association
Swedish Neurological Society
International Physicians for the Prevention of Nuclear War

Honors

The Hwasserska Prize (Uppsala Medical Society) for meritorious scientific work 2010
The Åke Ljungdahl Prize (The Research Foundation of The Swedish Parkinson´s Disease Association)

2011

CV Cecilia Lundberg

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed for Form Page 2.
Follow the sample format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME	POSITION TITLE
Cecilia Lundberg	Professor

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	YEAR(s)	FIELD OF STUDY
Porthälla gymnasium, Sweden	baccalaureate	1986	Natural sciences
Lund University, Sweden	B.Sc.	1990	Medicine
Lund University, Sweden	Ph. D.	1996	Neurobiology
Harvard Medical School, Boston	Post-doc	1996-1998	Gene therapy
Lund University, Sweden	Docent	2002	Neurobiology

NOTE: The Biographical Sketch may not exceed four pages. Items A and B (together) may not exceed two of the four-page limit. Follow the formats and instructions on the attached sample.

3. Positions and Honors.

Professional Positions

exceed two of the four-page limit. Follow the formats and instructions on the attached sample.

3. Positions and Honors.

Professional Positions

1990-1996 PhD student in Prof Anders Björklund's lab at the Dept. Medical Cell Research, Lund University Sweden.

1996-1998 Post-doctoral Fellow in Prof Richard C Mulligan's lab at Children's Hospital, Harvard Medical School, Boston.

1999-2002 Assistant professor at the Wallenberg Neuroscience Center, Dept Physiological Sciences, Lund University, Sweden.

1999-present Head of independent research group at Wallenberg Neuroscience Center. Main supervisor of 6 PhD students.

2002 Associate professor (Docent).

2002-2004 Lecturer in biomedicine (half-time)

2007-2009 Deputy chairman Dept Experimental Medical Sciences, Lund University

2009-2010 Lecturer in Neurobiology, tenured full time

2011-present Professor in Neurobiology, Lund University

2012-present Vice dean Medical faculty, Lund University

Honors, Awards, Other Professional Activities

1998 Awarded Wenner-Gren Post Doctoral Fellowship 5 years of funding for post-doctoral training

2000-present Secretary Neurobiological Club at Lund University

2001 Member of the organizing committee for the Gene Therapy Network meeting, 26-27 March 2001at the Wenner-Gren Center, Stockholm

2001-2005 Director of graduate studies at the Dept Physiological Sciences, Lund University

2002-2005 Editor of Basic Science on Lund Virtual Medical Journal (LVMJ) ISSN 1652-0971

2002-2007 Treasurer Swedish Society for Gene Therapy

2006-present Evaluation committee member of the Swedish Research Council

2007-present Evaluation committee member of the Norwegian Research Council

Ad hoc referee for different journals, including:
Experimental Neurology, Proceedings of the National Academy of Science USA, Neuroscience, Experimental Cell Research, Brain Research, Cell Transplantation, Gene Therapy, Stem Cells, Journal of Neurochemistry, Molecular Therapy

4. Selected peer-reviewed publications (in chronological order). (Selected from approx. 75 peer-reviewed publications and 15 book chapter and reviews)

1. C.Lundberg, S.J. Jungles and R.C. Mulligan, "Increased efficacy of leptin by intracranial gene transfer in obese mice using recombinant adeno-associated vectors." Nature Biotechnology February 2001 Volume 19 Number 2 pp 169 - 172
2. U Englund, R.A Fricker-Gates, C Lundberg, A Björklund and K Wictorin "Transplantation of Human Neural Progenitor Cells into the Neonatal Rat Brain: Extensive Migration and Differentiation with Long-distance Axonal Projections" Exp Neurol. 2002 Jan; 173(1): 1-21.
3. Lundberg, U. Englund, D. Trono, A. Björklund, K. Wictorin "Differentiation of the RN33B cell line into forebrain projection neurons after transplantation into the neonatal rat brain" Exp Neurol. 2002 Jun;175(2):370-87
4. Ericson, K Wictorin and C Lundberg "Ex vivo and in vivo studies of transgene expression in rat atrsocytes transduced with lentiviral vectors. Exp Neurol. 2002 Jan; 173(1): 1-21.
5. Georgievska, D Kirik, C Rosenblad, C Lundberg, A Björklund. "Overexpression of GDNF in the striatum by a recombinant lentiviral vector provides preservation and sprouting of the nigrostriatal dopamine pathway in the 6-hydrooxydopamine lesion model.".Neuroreport. 2002 Jan 21;13(1):75-82.
6. Kirik, C Rosenblad, C Burger, C Lundberg, TE Johansen, N Muzyczka, RJ Mandel, A Björklund "Parkinson-like neurodegeneration induced by overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci. 2002 Apr 1;22(7):2780-91.
7. Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P. "Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line." J Biol Chem. 2002 Oct 11;277(41):38884-94.
8. J Jakobsson, C Ericson, M Jansson, E Björk and C Lundberg "Targeted transgene expression in rat brain using lentiviral vectors". J Neurosci Res. 2003 Sep 15;73(6):876-85.
9. Arvidsson A, Kirik D, Lundberg C, Mandel RJ, Andsberg G, Kokaia Z, Lindvall O. "Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats." Neurobiol Dis. 2003 Dec;14(3):542-56.
10. Jakobsson J, Georgievska B, Ericson C, Lundberg C."Lesion-dependent regulation of transgene expression in the rat brain using a human glial fibrillary acidic protein-lentiviral vector." Eur J Neurosci. 2004 Feb;19(3):761-5.
11. Jakobsson J, Rosenqvist N, Thompson L, Lundberg C "Dynamics of transgene expression in a neural stem cell line transduced with lentiviral vectors incorporating the cHS4-insulator." Exp Cell Res. 2004 Aug 15;298(2):611-23.
12. Georgievska B, Jakobsson J, Persson E, Ericson C, Kirik D, Lundberg C "Regulated

11. Jakobsson J, Rosenqvist N, Thompson E, Lundberg C "Dynamics of transgene expression in a neural stem cell line transduced with lentiviral vectors incorporating the cHS4-insulator." Exp Cell Res. 2004 Aug 15;298(2):611-23.
12. Georgievska B, Jakobsson J, Persson E, Ericson C, Kirik D Lundberg C "Regulated delivery of GDNF in the rat striatum using a tetracycline-dependent lentiviral vector" Hum Gene Ther. 2004 Oct;15(10):934-44.
13. Jakobsson J, Lundberg C. Lentiviral Vectors for Use in the Central Nervous System. Mol Ther. 2006 Jan 2;
14. Jakobsson J, Nielsen TT, Staflin K, Georgievska B, Lundberg C. Efficient transduction of neurons using Ross River glycoprotein-pseudotyped lentiviral vectors. Gene Ther. 2006 Jun;13(12):966-73. Epub 2006 Mar 2.
15. Jakobsson J, Rosenqvist N, Marild K, V Agoston D, Lundberg C. Evidence for disease-regulated transgene expression in the brain with use of lentiviral vectors.J Neurosci Res. 2006 Jul;84(1):58-67.
16. Rogelius N, Jensen JB, Lundberg C, Parmar M. Retrovirally delivered Islet-1 increases recruitment of Ng2 expressing cells from the postnatal SVZ into the striatum.Exp Neurol. 2006 Jun 23; [Epub ahead of print]
17. Rogelius N, Hebsgaard JB, Lundberg C, Parmar M. "Reprogramming of neonatal SVZ progenitors by islet-1 and neurogenin-2." Mol Cell Neurosci. 2008 Jul;38(3):453-9. Epub 2008 Apr 24.
18. Lundberg C, Björklund T, Carlsson T, Jakobsson J, Hantraye P, Déglon N, Kirik D. "Applications of lentiviral vectors for biology and gene therapy of neurological disorders." Curr Gene Ther. 2008 Dec;8(6):461-73.
19. Nielsen TT, Marion I, Hasholt L, Lundberg C. "Neuron-specific RNA interference using lentiviral vectors." J Gene Med. 2009 Jul;11(7):559-69.
20. Tønnesen J, Sørensen AT, Deisseroth K, Lundberg C, Kokaia M. "Optogenetic control of epileptiform activity." Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12162-7. Epub 2009 Jul 6.
21. Horvath L, van Marion I, Taï K, Nielsen TT, Lundberg C. Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease. J Gene Med. 2011 Mar;13(3):188-97. doi: 10.1002/jgm.1555.
22. Tønnesen J, Parish CL, Sørensen AT, Andersson A, Lundberg C, Deisseroth K, Arenas E, Lindvall O, Kokaia M.
23. Functional integration of grafted neural stem cell-derived dopaminergic neurons monitored by optogenetics in an in vitro Parkinson model. PLoS One. 2011 Mar 4;6(3):e17560.
24. Sørensen AT, Rogelius N, Lundberg C, Kokaia M. Activity-dependent long-term plasticity of afferent synapses on grafted stem/progenitor cell-derived neurons. Exp Neurol. 2011 Jun;229(2):274-81. Epub 2011 Feb 12.
25. Lindgren N, Francardo V, Quintino L, Lundberg C, Cenci A A Model of GDNF Gene Therapy in Mice with 6-Hydroxydopamine Lesions: Time Course of Neurorestorative Effects and ERK1/2 ActivationJournal of Parkinson's Disease, 2012; 2: 333-47.
26. Wettergren EE, Gussing F, Quintino L, Lundberg CNovel disease-specific promoters for use in gene therapy for Parkinson's disease.Neurosci Let 2012 Nov 14;530(1):29-34. Epub 2012 Oct 12.
27. Tai K, Quintino L, Isaksson C, Gussing F, Lundberg C.Destabilizing domains mediate reversible transgene expression in the brain.PLoS One. 2012;7(9):e46269. Epub 2012 Sep 28.
28. Quintino L, Baudet A, Larsson J, Lundberg CFACS binding assay for analysing GDNF interactionsJ Neurosci Methods. 2013 Aug 15;218(1):25-8
29. Quintino L, Manfre G, Elgstrand Wettergren E, Namislo A, Isaksson C, Lundberg CFunctional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's DiseaseMol Ther. 2013 Jul 24.
30. Åkerblom M, Sachdeva R, Quintino L, Elgstrand Wettergren E, Chapman K Z, Manfre G, Lindvall O, Lundberg C, Jakobsson JVisualization and genetic modification of resident brain microglia using lentiviral vectors regulated by microRNA-9Nature Communications 4, Article number: 1770. Published 23 April 2013.

CV Åsa Mackenzie

Name: Åsa Mackenzie
Home address: Ekolnsvägen 13A, 756 53 Uppsala, Phone: +46-18-314030, +46-725326755
Work address: Dept of Comparative Physiology, Norbyvägen 18A, 752 36 Uppsala, SWEDEN, Phone: +46-18-471 6419, Fax: +46-18-471 6425
Home page: http://www.iob.uu.se/forskning/jamforande-fysiologi/mackenzie-lab/
E-mail: asa.mackenzie@neuro.uu.se
Date and place of birth: August 28, 1971, Uppsala, Sweden
Nationality: Swedish
Marital status: Married to Nicholas Mackenzie. Children: Stella (11 ys), Peggy (9 ys) and Amy (4 ys). Total maternity leave 2 years 8 months.

Nationality: Swedish
Marital status: Married to Nicholas Mackenzie. Children: Stella (11 ys), Peggy (9 ys) and Amy (4 ys). Total maternity leave 2 years 8 months.

Education and Positions
1991-1996 MSc1996, Biochemistry, Uppsala University (UU).
1997-2002 PhD in Medicine, Cell and Molecular Biology at Karolinska Institutet: ”Some aspects of nuclear receptor function in the CNS – Novel roles of Nurr1 and RXR in developing and mature neurons”. Supervisor Prof. *Thomas Perlmann*. Faculty opponent: Prof. *Kenneth Campbell*, US.
2002-2005 Post-doc at AstraZeneca Transgenics/Comparative Genomics and Molecular Neurobiology, AstraZeneca, Gothenburg.
2005-2008 Post-doc Uppsala University, Dept of Neuroscience.
2008-2010 Assistant Prof and Group Leader, UU, Dept of Neuroscience.
2010-2014 Associate Prof and Group Leader, UU, Dept of Neuroscience.
2014-2015 Associate Prof and Head, Unit of Functional Neurobiology, UU.
2015- Professor at Dept of Comparative Physiology; Chair in Molecular Physiology

Appointments, Honor, Evaluation & Board participation
2013- V. Chairman *Expert Board for Lab Animal Science* Swedish Research Council.
2009- Member of board for the main seminar series at the Biomedical center, UU.
2008-2011 Member of Faculty board for anti-discrimination policy, UU.
2014 Awarded ”Scientist of the month” for my work on basic research around Parkinson´s disease by the Swedish Brain Foundation.
2014 Evaluation report for the Chair in Molecular Physiology at UU: ”*Clearly potential researcher with international visibility. Potential candidate to this position due to highly competitive research program … Can be considered as a very promising ”rising star”. Own funding. Strong publications.” ”Mackenzie has published 20 articles in internationally very well recognized journals. Promising scientist*”.
2015 Recruited to the position as Chair in Molecular Physiology.

Funding (Main PI in all)
Current:
2014-2017 Swedish Research Council (SMRC; Vetenskapsrådet (VR)); Category: ”Natural Sciences”;
2015-2017 SMRC (VR); Category: ”Medicine”;
2014 The Swedish Parkinson Foundation (Parkinsonfonden);
2014, 2015 The Swedish Brain Foundation (Hjärnfonden),

Previous:
2008-2011 SMRC (VR))-”Medicine” + a number of private foundations, incl Wiberg, Åhlén, Bergwall.
2011-2014 SMRC (VR) -”Medicine” + private brain foundations.
2008-2013 The Swedish Parkinson Foundation (Parkinsonfonden).
2009, 2012 The Swedish Brain Foundation (Hjärnfonden).

Funded networks
Current:
2014-2016 ERA-NET Neuron ”Mental disorders”: EU network on Addiction headed by Prof El Mestikawy; ranked 2 out of all proposals.

Previous:
2009-2012 Nordic Co-transmission Network (STINT-funded): Mackenzie Initiative/head.
2009-2013 Dopamine diseases (VR-funded): Mackenzie Initiative, Prof Lars Olson head.
2012-2014 Joint Brazilian-Swedish Collaboration (STINT-funded): Mackenzie co-applicant.

Invited speaker at international meetings
1. Labex 2014: “From Synapses to Psychiatric Disorders”, Nov 7, 2014, Collège de France, Paris, France.
2. SFN *mini-convention* org:d by NIH/NIDA, “Emerging and Novel Aspects of

1. Labex 2014: "From Synapses to Psychiatric Disorders", Nov 7, 2014, Collège de France, Paris, France.
2. SFN mini-convention org:d by NIH/NIDA, "Emerging and Novel Aspects of Neuronal Transmission" Nov 8, 2013, San Diego, USA. *Only speaker invited outside US top-ranked universities*. Cancelled due to the temporary close-down of NIH.
3. Dopamine 2013, May 24-28, 2013, Sardinia, Italy.
4. French Neuroscience Meeting, May 21-23, 2013, Lyon, France.
5. ECNP: Eur College Neuropsychopharmacol, October 14-17, 2012, Vienna, Austria.
6. The Scandinavian Physiological Society, Aug 14-16, 2009, Uppsala.
7. *Imaging, Genetics and Other Nifty Techniques in Neurophysiology", Jan 18-20, 2010, Natal, Brazil*

Organizer of international meetings

1. A Christmas Neuroscience Symposium (CNS) on Glutamate Transporters (Dec 2011).
2. A Christmas Neuroscience Symposium (CNS) on Parkinson´s disease (Dec 2013).
3. Organizer of session at IBANGS in Uppsala 2015 ("Cotransmission in the basal ganglia").

Thesis evaluations

***Sweden*: Anna Lord, UU, 2009; Jenny Häggkvist, UU, 2009; Helena Åkerberg, UU, 2009; Linda Järdestad, UU, 2011; Thomas Nässtrom, UU, 2011; Carly Kiselyczyk, KI, 2012; Richard Andersson, KI, 2012; Jenny Johansson, UU, 2013; Alfhild Grönblad, UU, 2013; *International*: Diana Yae Sakae, Paris, Université Pierre et Marie Curie, April 11, 2014.**

Leadership and pedagogical training

1. Project Management – Wenell (UU), 2007
2. Supervision of Case studies at the Medical Faculty (UU), 2008.
3. Pedagogy for University Lecturers (UU), 2008.
4. Pedagogy for PhD student supervisors (UU), 2009-10.
5. Media-training course at SMRC/VR 2010.
6. Leadership course for women employed at Uppsala Universitet, UU, 2013.
7. More than 250 hours of teaching, incl Biomedical and Medical programs.
8. Course head Neurobiology with Pharmacology (15 hp, Biomedical Program) 2012-14.

Supervision (postdocs and doctors and for whom I have been main supervisor):

Doctoral degree:

1. Karin Nordenankar, April 20, 2012: *Functional Analysis of the Vesicular Glutamate Transporter 2 in Specific Neuronal Circuits of the Brain,* Faculty opponent Prof. Rainer Spanagel, Heidelberg, Germany;
2. Emma Arvidsson, Oct 3, 2014: *Motion and Emotion. In Vivo Analysis of the Mouse Basal Ganglia*. Faculty opponent: Prof Cecilia Flores, Montreal, Canada;
3. Stefano Pupe, March 24, 2015, Natal (Brazil)-Uppsala Joint PhD degree.

4. Planned defences: Nadine Schweizer, March 2016; Thomas Viereckel, Dec 2017; Julia Pedersen, Jan 2018.

Postdocs:

Current:

Maria Papathanou 2015-2017; Stéfano Pupe 2015, Emma Arvidsson 2015.

Previous:

Hillevi Englund 2009, Tobias Johansson 2010, Johan Alsiö* 2010, Carolina Birgner 2009-11, Casey Smith 2009-12, Aparna Rajagopalan 2010-11, Ernesto Restrepo-Leidefors 2011-2013.
*Together with Trevor Robbins at Cambridge Univ, England, I am supervisor for Dr Johan Alsiö, International postdoc supported by VR-M 2012-current.

International and national collaborations:

I have been fortunate to come in contact with prominent scientists worldwide who have

International and national collaborations:
I have been fortunate to come in contact with prominent scientists worldwide who have been interested in my work and I have thereby been able to form a substantial and meaningful network. *In Sweden and Switzerland*: **Christian Luscher (AMPA/NMDA recordings Geneva), Sylvie Dumas (Quntitative in situ hybridization, Paris), Richardson Leao (electrophysiology/optogenetics, UU), Malin Lagerström (mouse genetics, UU), Martin Lundblad (optogenetic-*in vivo* amperometry, Lund).** *In the US and Canada*: **Louis-Eric Trudeau* (cotransmission, Université de Montréal, UdeM), Daniel Levesque (biochemistry, UdeM), Salah El Mestikawy* and Bruno Giros (VGLUT3/VMAT2, McGill, Montreal), Marisela Morales (*in situ* hybridization, NIH, Baltimore), Satoshi Ikemoto (optogenetic tetrode electrophysiology, NIH, Baltimore), Trevor Robbins (reinforcement, Cambridge; *cosupervisor and host at Cambridge for Johan Alsiö, International postdoc supported by VR-M.) Together with Trudeau and El Mestikawy, I formed the scientific network "Nordic Cotransmission Network" (supported by STINT 2009-2013); our first joint article was published in Nature Reviews Neuroscience 2011 and together with Trudeau and senior colleagues, I published a new review earlier this year: The multilingual nature of dopamine neurons), Prog. Brain Res. 2014.***

PUBLICATION LIST

1. Cre-driven optogenetics in the heterogeneous genetic panorama of the VTA.
Pupe S, Wallén-Mackenzie Å. ***Trends Neurosci***. 2015 May 8. pii: S0166-2236(15)00083-1. doi: 10.1016/j.tins.2015.04.005. Review. PMID: 25962754

2.Targeted deletion of Vglut2 expression in the embryonal telencephalon promotes an anxiolytic phenotype of the adult mouse. Nordenankar K, Bergfors A, Wallén-Mackenzie Å. ***Ups J Med Sci***. 2015 Apr 9:1-13. PMID: 25857802

3.Reply to Konsolaki and Skaliora: Habituation, hyperlocomotion, and "genuine hyperlocomotion". Pupe S, Schweizer N, Wallén-Mackenzie Å. ***Proc Natl Acad Sci U S A***. 2015 Jan 6;112(1):E5. doi: 10.1073/pnas.1417574112. PMID: 25540419

4. SLC10A4 is a vesicular amine-associated transporter modulating dopamine homeostasis. Larhammar M, Patra K, Blunder M, Emilsson L, Peuckert C, Arvidsson E, …, Jahn R, Wallén-Mackenzie Å, Kullander K. ***Biol Psychiatry.*** 2015 Mar 15;77(6):526-36. doi: 10.1016/j.biopsych.2014.07.017. PMID: 25176177

5. Reduced gene expression levels of Munc13-1 and additional components of the presynaptic exocytosis machinery upon conditional targeting of Vglut2 in the adolescent mouse. Rajagopalan A, Schweizer N, Nordenankar K, Nilufar Jahan S, Emilsson L, Wallén-Mackenzie A. ***Synapse***. 2014 Aug 19. doi: 10.1002/syn.21776. PMID: 25139798

6. The multilingual nature of dopamine neurons. Trudeau LE, Hnasko TS, Wallén-Mackenzie A, Morales M, Rayport S, Sulzer D. ***Prog Brain Res***. 2014;211:141-64. doi: 10.1016/B978-0-444-63425-2.00006-4. Review.
PMID: 24968779

7. Haplotype-tag single nucleotide polymorphism analysis of the vesicular glutamate transporter (VGLUT) genes in severely alcoholic women. Comasco E, Hallman J, Wallén-Mackenzie A. ***Psychiatry Res.*** 2014 Oct 30;219(2):403-5. doi: 10.1016/j.psychres.2014.05.052. Epub 2014 Jun 6. PMID: 24953423

8. Age- and sex-dependence of dopamine release and capacity for recovery identified in the dorsal striatum of C57/Bl6J mice. Arvidsson E, Viereckel T, Mikulovic S, Wallén-Mackenzie Å. ***PLoS One***. 2014 Jun 12;9(6):e99592. doi: 10.1371/journal.pone.0099592. PMID: 24925086

9. Limiting glutamate transmission in a Vglut2-expressing subpopulation of the subthalamic nucleus is sufficient to cause hyperlocomotion. Schweizer N, Pupe S, Arvidsson E, Nordenankar K, Smith-Anttila CJ, Mahmoudi S, Andrén A, Dumas S, Rajagopalan A,

9. Limiting glutamate transmission in a Vglut2-expressing subpopulation of the subthalamic nucleus is sufficient to cause hyperlocomotion. Schweizer N, Pupe S, Arvidsson E, Nordenankar K, Smith-Anttila CJ, Mahmoudi S, Andrén A, Dumas S, Rajagopalan A, Lévesque D, Leão RN, Wallén-Mackenzie Å. ***Proc Natl Acad Sci U S A.*** 2014 May 27;111(21):7837-42. doi: 10.1073/pnas.1323499111. PMID: 24821804

10. Increased hippocampal excitability and impaired spatial memory function in mice lacking VGLUT2 selectively in neurons defined by tyrosine hydroxylase promoter activity. Nordenankar K, Smith-Anttila CJ, Schweizer N, Viereckel T, Birgner C, Mejia-Toiber J, Morales M, Leao RN, Wallén-Mackenzie A. ***Brain Struct Funct***. 2014 May 7. PMID: 24802380

11.Glutamate corelease promotes growth and survival of midbrain dopamine neurons. Fortin GM, Bourque MJ, Mendez JA, Leo D, Nordenankar K, Birgner C, Arvidsson E, Rymar VV, Bérubé-Carrière N, Claveau AM, Descarries L, Sadikot AF, Wallén-Mackenzie Å, Trudeau LÉ. ***J Neurosci.*** 2012 Nov 28;32(48):17477-91. doi: 10.1523/JNEUROSCI.1939-12.2012. PMID: 23197738

12. Ultrastructural characterization of the mesostriatal dopamine innervation in mice, including two mouse lines of conditional VGLUT2 knockout in dopamine neurons. Bérubé-Carrière N, Guay G, Fortin GM, Kullander K, Olson L, Wallén-Mackenzie Å, Trudeau LE, Descarries L. ***Eur J Neurosci***. 2012 Feb;35(4):527-38. doi: 10.1111/j.1460-9568.2012.07992.x. PMID: 22330100

13. Enhanced sucrose and cocaine self-administration and cue-induced drug seeking after loss of VGLUT2 in midbrain dopamine neurons in mice. Alsiö J, Nordenankar K, Arvidsson E, Birgner C, Mahmoudi S, Halbout B, Smith C, Fortin GM, Olson L, Descarries L, Trudeau LÉ, Kullander K, Lévesque D, Wallén-Mackenzie A. ***J Neurosci***. 2011 Aug 31;31(35):12593-603. doi: 10.1523/JNEUROSCI.2397-11.2011.
PMID: 21880920

14. From glutamate co-release to vesicular synergy: vesicular glutamate transporters. El Mestikawy S, Wallén-Mackenzie A, Fortin GM, Descarries L, Trudeau LE. ***Nat Rev Neurosci***. 2011 Apr;12(4):204-16. doi: 10.1038/nrn2969. Review. PMID: 21415847

15 .A sensory subpopulation depends on vesicular glutamate transporter 2 for mechanical pain, and together with substance P, inflammatory pain. Lagerström MC, Rogoz K, Abrahamsen B, Lind AL, Olund C, Smith C, Mendez JA, Wallén-Mackenzie Å, Wood JN, Kullander K. ***Proc Natl Acad Sci U S A***. 2011 Apr 5;108(14):5789-94. doi: 10.1073/pnas.1013602108. Epub 2011 Mar 17. PMID: 21415372

16. VGLUT2-dependent sensory neurons in the TRPV1 population regulate pain and itch. Lagerström MC, Rogoz K, Abrahamsen B, Persson E, Reinius B, Nordenankar K, Olund C, Smith C, Mendez JA, Chen ZF, Wood JN, Wallén-Mackenzie A, Kullander K. ***Neuron***. 2010 Nov 4;68(3):529-42. doi: 10.1016/j.neuron.2010.09.016. PMID: 21040852

17. Genetic inactivation of the vesicular glutamate transporter 2 (VGLUT2) in the mouse: what have we learnt about functional glutamatergic neurotransmission? Wallén-Mackenzie A, Wootz H, Englund H. ***Ups J Med Sci***. 2010 Feb;115(1):11-20. doi: 10.3109/03009730903572073. Review. PMID: 20187846

18. VGLUT2 in dopamine neurons is required for psychostimulant-induced behavioral activation. Birgner C, Nordenankar K, Lundblad M, Mendez JA, Smith C, le Grevès M, Galter D, Olson L, Fredriksson A, Trudeau LE, Kullander K, Wallén-Mackenzie A. ***Proc Natl Acad Sci U S A***. 2010 Jan 5;107(1):389-94. doi: 10.1073/pnas.0910986107. Epub 2009 Dec 14. PMID: 20018672

In press 2015:
Bagchi S, Fredriksson R, Wallén-Mackenzie Å. The Proximity Ligation Assay in cells and tissue; ELISA – Methods and Protocols, Publisher: Springer Science and Business Media; Book Series: ***Methods in Molecular Biology: Springer protocols***, Series Editor JM Walker, Book Editor RM Hnasko. *Methods in Molecular Biology 1318*; 2015; ISBN 978-1-4939-2741-8

Book Series: ***Methods in Molecular Biology: Springer protocols***, Series Editor JM Walker, Book Editor RM Hnasko. *Methods in Molecular Biology 1318*; 2015; ISBN 978-1-4939-2741-8.

CV Lennart Pettersson

Adress: Nunnevägen 1, 134 34 Gustavsberg
Telefon: 08-57035120
E-post: lennartpettersson1@yahoo.se
Ålder: 72 år (2014)

Utbildning

a) Fil.kand. vid Stockholms universitet 1966 (genetik, zoologi och mikrobiologi, 2 betyg av varje)
b) Översiktskurs i miljövård (10 poäng) vid Lunds universitet 1970
c) Tre betyg i mikrobiologi vid Stockholms universitet 1974
d) Grundkurs i klinisk läkemedelsprövning 1991
e) Allmän patologi, 10 poäng, vid Karolinska institutet 1993
f) Diverse datakurser

Anställningar

a) Pharmacia 1967-1969 (medicinsk redaktör inom området infusionslösningar)
b) Sockerbolaget 1969-1971 (mikrobiologiskt utvecklingsarbete)
c) Arla 1971-1983 (mikrobiologiskt utvecklingsarbete)
d) STU/NUTEK 1983-1996 (bioteknikhandläggare med ansvar för såväl kommersiella utvecklingsprojekt som för forskningsprogram inom områden som genteknik, protein enginneeering, kolhydratkemi, peptidteknologi, bioteknisk processteknik och bioteknisk separationsteknik)
e) Regeringskansliet (Jordbruksdepartementet) 1996-2005 (handläggning av ärenden relaterade till genteknik- och genresursfrågor, deltog i internationella förhandlingar om jordbrukets växtgenetiska resurser inom ramen för FAO)

Övrigt

a) Har representerat STU/NUTEK i t.ex. Nordisk Industrifond, MFR:s genomgrupp, programstyrelsen för Stiftelsen Bioteknisk Forskning, EU:s grupp inom protein engineering, tekniska kommitten för COST-projekt inom agrikultur och bioteknik och SIK:s industriella råd
b) Svensk representant i Nordiska Genbankens styrelse 1996-2003
c) Spelar bordtennis, går i fjällen, åker längdskidor, läser böcker och är som folk är mest

CV Martin Ingelsson

Office Address:	Uppsala University, Rudbeck Laboratory, Dag Hammarskjölds väg 20, 751 85 Uppsala. Sweden
Home Address:	Norbyvägen 44B, 752 39 Uppsala, Sweden
Work Phone:	+46184714107
Work Email:	martin.ingelsson@pubcare.uu.se
Work FAX:	+464714808
Place of Birth:	Husie, Sweden

Education

Birth:

Education

1995: MD; Karolinska Institutet
2001: PhD; Karolinska Institutet

Postdoctoral Training

09/01-12/04: Post-doctoral Fellowship; Harvard Medical School/ Massachusetts General Hospital

Faculty Academic Appointments

12/09-ongoing: Associate Professor; Uppsala University
08/14-07/15: Visiting Associate Professor; Harvard Medical School

Appointments at Hospitals/Affiliated Institutions

05/98-05/01: Internship at Karolinska University Hospital
01/05-12/12: Clinical Residency at the Geriatric Dept, Uppsala University Hospital
12/12 - ongoing: Specialist in Geriatrics; Uppsala University Hospital
14/08- ongoing: Research Sabbatical / Massachusetts General Hospital

Major Administrative Leadership Positions

Local
12/09- : Member of the Research Committee at the Geriatric Department; Uppsala University Hospital
12/09- : Member of the Steering Committee at the Geriatric Laboratory; Uppsala University

Professional Societies

06/95- : Member of the Swedish Society of Medicine
01/97- : Member of the Society for Neuroscience

Grant Review Activities

01/10- : Alzheimer's Association; Grant Reviewer

Report of Local Teaching and Training

Teaching of Students in Courses

PhD student supervision
2005-2008: Supervision of PhD student (Elin Blom); Uppsala University
2005-2009: Supervision of PhD student (Lena Skoglund); Uppsala University
2007-2011: Supervision of PhD student (Thomas Nässtrom); Uppsala University
2008-2013: Supervision of PhD student (Therese Fagerqvist); Uppsala University
2012-2015 :Supervision of PhD student (Gabriel Westman); Uppsala University
2012- : Supervision of PhD student (Gabriel Gustafsson); Uppsala University
2013- : Supervision of PhD student (Leire Almandoz-Gil); Uppsala University

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

2009- : Supervision of post-doctoral fellow (Veronica Lindström); Uppsala University
2010-2013: Supervision of post-doctoral fellow (Hedvig Welander); Uppsala University
2013- : Supervision of post-doctoral fellow (Elisabet Ihse); Uppsala University
2014- : Supervision of post-doctoral fellow (Sara Ekmark-Lewén); Uppsala University

Clinical Supervisory and Training Responsibilities

2011-2012: Supervision of MD students for their training in Geriatric medicine; Uppsala University Hospital

Laboratory and Other Research Supervisory and Training Responsibilities

2003: Supervision of an Honor's Thesis student (Jung Lee) (2 semesters); Harvard

Laboratory and Other Research Supervisory and Training Responsibilities

2003: Supervision of an Honor's Thesis student (Jung Lee) (2 semesters); Harvard College
2005: Supervision of a Master's thesis student (Johan Fredriksson) (20 weeks); Linköping University
Supervision of a Master's thesis student (Thomas Nässtrom) (20 weeks); Mälardalen University
2006: Supervision of a Master's thesis student (Jayashree Viswanathan) (20 weeks); Skövde University
Supervision of an M.D. student- project work (Sara Sylvén) (5 weeks); Uppsala University
2007: Supervision of a Master's thesis student (Therese Wahlberg) (20 weeks); Uppsala University
Supervision of a Master's thesis student (Yijing Wang) (20 weeks); Uppsala University
Supervision of a Biomedical student- project work (Kristin Sandberg) (10 weeks); Uppsala University
2008: Supervision of a Master's thesis student (Vanessa Silva) (20 weeks); Uppsala University
Main supervisor of a Master's thesis student (Anna Börjesson) (20 weeks); Chalmers University
2010: Supervision of an M.D. student – project work (Mikael Barbu) (20 weeks); Uppsala University
2012: Supervision of an M.D. student – project work (Xingjian Su) (20 weeks); Uppsala University

Report of Regional, National and International Invited Teaching and Presentations

National
2006: Invited speaker at the symposia "Biobanking in the 21st century", The Swedish National Biobank Program; Uppsala, Sweden
2007: Invited speaker at the "Annual Meeting for The Swedish Society for Cognitive Illnesses"; Uppsala, Sweden
2007: Invited symposia speaker at SwedenBIOs Key Scientist Day; Stockholm, Sweden
2008: Invited symposia speaker at the "National Dementia Day", Stockholm, Sweden
2008: Invited speaker at the symposia "Pharmacological treatment of Alzheimer's disease"; Uppsala, Sweden (arranged by The Swedish Society for Cognitive Illnesses)
2011: Invited speaker at the symposia "Pharmacological treatment of Alzheimer's disease"; Uppsala, Sweden (arranged by The Swedish Society for Cognitive Illnesses)
2013: Invited speaker at the "Swedish Neurology Association's Spring meeting"; Falun, Sweden
2013: Invited speaker at the "National Dementia Day"; Stockholm, Sweden

International
2008: Invited speaker at "Reunión del Grupo de Estudio de Conductas y Demencias de la Sociedad Española de Neurología"; Barcelona, Spain
2008: Invited speaker at the "Springfield symposium on advances in AD therapy"; Geneva, Switzerland
2009: Organizer and speaker at the "Firat International Conference on Neurodegenerative Disorders: Immunotherapy and Biomarkers"; Uppsala, Sweden
2011: Organizer and speaker at the "Second International Conference on Neurodegenerative Disorders: Immunotherapy and Biomarkers"; Uppsala, Sweden
2013: Organizer and speaker at the "Third International Conference on Neurodegenerative Disorders: Immunotherapy and Biomarkers"; Uppsala, Sweden
2013: Invited speaker at the "TRANS MED meeting" at the Academy of Athens; Athens, Greece
2013: Invited speaker at the "13th Scandinavian Meeting on Parkinson's Disease"; Stockholm, Sweden
2014: Invited speaker at the "American Academy of Neurology", Philadelphia, USA
2015: Invited speaker at the "15th Scandinavian Meeting on Parkinson´s disease and

Stockholm, Sweden
2014: Invited speaker at the "American Academy of Neurology", Philadelphia, USA
2015: Invited speaker at the "15th Scandinavian Meeting on Parkinson´s disease and Related disorders"; Stockholm, Sweden

Report of Clinical Activities and Innovations

Current Licensure and Certification

1995: Medical license
2012: Specialty license in Geriatric Medicine

Practice Activities

1996-1998: Clinical training at the Geriatric Department/ Karolinska University Hospital; 50%
1998-2001: Internship at Karolinska University Hospital; 50%
2005-2012: Residency at the Geriatric Department/ Uppsala University Hospital; 75%

Report of Technological and Other Scientific Innovations

Patents:
Lars Lannfelt, Joakim Bergström, Martin Ingelsson, Pär Gellerfors. Antibodies and vaccines for use in therapeutic and diagnostic methods for Parkinson's disease, dementia with Lewy bodies and other neurodegenerative disorders, 61/048,865

The patent describes the generation and characterization of monoclonal antibodies that have been raised in our laboratory together with researchers at BioArctic Neuroscience and that such antibodies can be used both as novel therapeutics and diagnostics for patients with Lewy body brain pathology.

Report of Education of Patients and Service to the Community

Activities

2005- : Planning and implementation of several lecture program and information meetings with patients and caregivers

Educational Material for Patients and the Lay Community

Books, monographs, articles and presentations in other media:
Ingelsson, M. Behandling av Alzheimers sjukdom- en del nytt under solen, Medikament nr. 3 2000, 99-102 (Swedish).
Landahl, P. Kilander, L., **Ingelsson, M.** O, min man- om den förbryllande sjukdomen frontallobsdemens; Gothia 2009 (Swedish).

Educational material or curricula developed for non-professional students:
Ingelsson, M.**, Lilius, L., Forsell, C., Shin, Y., Irizarry, M., Graff, C., Hyman, B.T. Genotyping of apolipoprotein E- comparative evaluation of different protocols. Curr Prot Hum Genet 2003, Unit 9.14 (9.14.1.-9.14.14).**

Report of Scholarship

Research investigations

*# 1. **Ingelsson, M.**, Vanmechelen, E., Lannfelt, L., Microtubule-associated protein tau in human fibroblasts with and without the Swedish mutation. Neurosci Lett 1996; 220(1):9-12.*

2. Forsell, C., Froelich, S., Axelman, K., Vestling, M., Cowburn, R.F., Lilius, L., Johnston, J.A., Engvall, B., Dahlkild, Å., **Ingelsson, M.**, St George-Hyslop, P.H., Lannfelt, L., A novel pathogenic mutation (Leu262Phe) found in the presenilin 1 gene in early-onset Alzheimer's Disease. Neurosci Lett 1997;234:1-4.

3. Bronge, L., Ferneus, S-E., Blomberg, M., **Ingelsson, M.**, Isberg, L., Lannfelt, L., Wahlund, L-O., White matter lesions in Alzheimer patients are influenced by Apolipoprotein E genotype. Dement Geriatr Cogn Disord 1999; 10:89-96.

4. **Ingelsson, M.**, Blomberg, M., Benedikz, E., Karlsson, E., Vanmechelen, E., Lannfelt, L., Tau immunoreactivity in human plasma but no obvious increase in

4. **Ingelsson, M.**, Blomberg, M., Benedikz, E., Karlsson, E., Vanmechelen, E., Lannfelt, L., Tau immunoreactivity in human plasma but no obvious increase in dementia. Dement Geriatr Cogn Disord 1999; 10:442-5.

5. **Ingelsson, M.**, Froelich Fabre, S., Lilius, L., Andersen, C., Almkvist, O., Viitanen, M., Wahlund, L-O., Lannfelt, L., Increased risk for frontotemporal dementia through interaction between tau polymorphisms and apolipoprotein E *e*4. Neuroreport 2001; 12(5):905-9.

6. Fukumoto, H., **Ingelsson, M.**, Gårevik, N., Wahlund, L-O., Nukina, N., Hyman, B.T., Rebeck, G.W., Irizarry, M. The proportion of apolipoprotein E4 levels in APOE e3/e4 heterozygotes is elevated in CSF relative to plasma, independent of Alzheimer disease diagnosis. Exp Neurol 2003; 183:249-253.

7. Dombeck, DA., Kasischke KA., Vishwasrao HD., **Ingelsson M.**, Hyman, B.T, Webb, W.W. Uniform polarity microtubule assemblies imaged in native brain tissue by second harmonic generation. Proc Natl Acad Sci USA 2003; 100 (12):7081-86.

8. **Ingelsson, M.**, Fukumoto, H., Newell, K., Growdon, J.H. Hedley-Whyte, T.E., Albert, M.S., Frosch, M.P., Hyman, B.T., Irizarry, MC. Early A[beta] accumulation and progressive synaptic loss, gliosis and tangle formation in AD brain. Neurology 2004; 62(6):925-31.

9. **Ingelsson, M.**, Jesneck, J., Irizarry, M.C., Hyman, B.T., Rebeck, G.W. Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease. Neurosci Lett 2004; 367:228-31.

 # 10. Bertram, L., Hiltunen, M., Parkinson, M., ***Ingelsson, M.****, Lange, C., Ramasamy, K., Mullin, K., Menon, R., Sampson, A.J., Hsiao, M.Y., Elliot, K.J., Velicelebi, G., Moscarillo, T., Hyman, B.T., Wagner, S.L., Becker, K.D., Blacker, D., Tanzi, R.E. Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med 2005; 352:884-94.*

11. Lee, J., Fukumoto, H., Orne, J., Klucken, J., Raju, S., Vanderburg, C., Irizarry, M., Hyman, B.T., **Ingelsson, M.** Decreased levels of BDNF protein in Alzheimer temporal cortex, independent of BDNF polymorphisms. Exp Neurol 2005; 194:91-96.

12. SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., **Ingelsson, M.**, Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., Forster, C., Yu, M., Orne, J., Janus, C., Mariash, A., Kuskowski, M., Hyman, B.T., Hutton, M., Ashe, K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005; 309:476-81.

13. Huang, W., Dobberfuhl, A., Filippopoulos, T., **Ingelsson, M.**, Fileta, J.B., Poulin, N.R. Grosskreutz, C.L. Transcriptional up-regulation and activation of intiating caspases in experimental glaucoma. Am J Pathol 2005; 167, 3:673-81.

14. Cantuti-Castelvetri, I., Klucken, J., **Ingelsson, M.**, Ramasamy, K., McLean, P.J., Frosch, M.P., Hyman, B.T., Standaert, D.G. Alpha-synuclein and chaperones in dementia with Lewy bodies. J Neuropathol Exp Neurol 2005; 6 (12):1058-66.

15. Klucken, J., Ingelsson, M., Shin, Y., Irizarry, M.C., Hedley-Whyte, E.T., Frosch, M., Growdon, J., McLean, P., Hyman, B.T. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. Acta Neuropathol 2006; 111(2):101-8.

16. Matsui, T., Ramasamy, K., **Ingelsson, M.**, Fukumoto, H., Conrad, C., Frosch, M.P., Irizarry, M.C., Yuan, J., Hyman, B.T. Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer's disease: relationship to formic acid extractable Aβ42 levels. J Neuropathol Exp Neurol 2006; 65(5):508-15.

 # 17. Ingelsson, M., Ramasamy, K., Cantuti-Castelvetri, I., Skoglund, L., Matsui, T., Orne, J., Kawa, H., Augustinack, J.C., de Silva, R., Lees, A.J., Lannfelt, L.

 # 17. Ingelsson, M., Ramasamy, K., Cantuti-Castelvetri, I., Skoglund, L., Matsui, T., Orne, J., Kowa, H., Augustinack, J.C., de Silva, R., Lees, A.J., Lannfelt, L., Vanderburg, C.R., Growdon, J.H., Frosch, M.P., Standaert, D.G., Irizarry, M.C., Hyman, B.T. No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain. Acta Neuropathol 2006; 112(4):439-49.

#18. Kim, M., Hersh, L., Leissring, M.A., **Ingelsson, M.,** Matsui, T., Farris, W., Lu, A., Hyman, B.T., Selkoe, D.J., Bertram, L., Tanzi, R.E. Decreased catalytic activity of the insulin degrading enzyme in chromosome 10-linked Alzheimer's disease families. J Biol Chem 2007; 282(11):7825-32.

19. Wollmer, M.A., Sleegers, K., **Ingelsson, M**., Zekanowski, C., Brouwers, N., Maruszak, A., Brunner, F., Huynh, K-D., Kilander, L., Brundin, R-M., Hedlund, M., Giedraitis, V., Glaser, A., Kapaki, E., Tsolaki, M., Molyva, D., Paraskevas, G.P., Thal, D., Barcikowska, M., Kuznicki, J., Lannfelt, L., van Broeckhoven, C., Nitsch, R.M., Hock, C., Papassotiropoulos, A. Association Study on Cholesterol-related Genes in Alzheimer's disease. Neurogenetics 2007; 8(3):179-88.

20. Matsui, T., **Ingelsson, M.,** Fukumoto, H., Ramasamy, K., Kowa, H., Frosch, M.P., Irizarry, M.C., Hyman, B.T., Expression of APP pathway mRNAs and proteins in Alzheimer's disease. Brain Res 2007, 1161:116-23.

21. **Ingelsson, M.**, Ramasamy, K., Russ, C., Freeman, S.,.Orne, J., Raju, S., Matsui, T., Growdon, J.H., Frosch, M.P., Ghetti, B., Brown, R.H., Irizarry, M., Hyman, B.T. Increase in the relative expression of tau with four microtubule binding repeat regions, but diminished total tau protein, in frontotemporal dementia and progressive supranuclear palsy brains. Acta Neuropathol 2007; 114(5):471-9.

22. Conrad, C., Zhu, J., Conrad, C., Schoenfeld, D., Fang, Z., **Ingelsson, M**., Stamm, S., Church, G., Hyman, B.T. Single Molecule Profiling of Tau Gene Expression in Alzheimer's Disease. J Neurochem 2007; 103(3):1228-36.

*# 23. Giedraitis, V., Sundelöf, J., Irizarry, M.C., Gårevik, N., Hyman, B.T., Wahlund, L-O., **Ingelsson, M.,** Lannfelt, L.Amyloid beta levels in CSF and plasma are correlated in non-demented individuals. Neurosci Lett 2007; 427(3):127-31.*

24. Blom, E., Viswanathan, J., Kilander, L., Helisalmi, S., Soininen, H., Lannfelt, L., **Ingelsson, M.**, Glaser, A., Hiltunen, M. Low prevalence of *APP* duplications in Swedish and Finnish patients with early onset Alzheimer's disease. Eur J Hum Genet 2008; 16(2):171-5.

25. Skoglund, L., Viitanen, M., Kalimo, H., Lannfelt, L., Eriksdotter Jönhagen, M., **Ingelsson, M.**, Glaser, A., Herva, R. The *tau S305S* mutation causes frontotemporal dementia with parkinsonian features. Eur J Neurology 2008; 15(2):156-61.

26. Sundelöf, J., Giedraitis, V., Irizarry, MC., Sundström, J., Ingelsson, E., Rönnemaa, E., Ärnlov, J., Wiberg, B., Degerman Gunnarsson, M., Hyman, BT., Basun, H., **Ingelsson, M**., Lannfelt, L., Kilander, L. High plasma Aβ40 is associated with reduced Alzheimer's disease risk in elderly men. Arch Neurol 2008; 65(2):256-63.

27. Basun, H., Bogdanovic, N., **Ingelsson, M.,** Almkvist, O., Näslund, J., Axelman, K., Bird, T.D.,Nochlin, D., Schellenberg, G.D., Wahlund, L-O. Lannfelt, L. Clinical and neuropathological features of the *Arctic APP* mutation causing early onset Alzheimer's disease. Arch Neurol 2008; 65(4):499-505.

28. O'Callaghan, P., Sandwall, E., Li, J-P., Yu, H., Guan, Z-Z., Ravid, R., van Kuppevelt, T.H., Nilsson, LNG., **Ingelsson, M.**, Hyman, B.T., Kalimo, H., Lindahl, U., Lannfelt, L., Zhang, Z. Accumulation of Heparan Sulfate with Aβ Deposits in Alzheimer's Disease and Tg2576 Mice; Implications for Glial Cells. Brain Pathol 2008; 18(4):548-61.

Alzheimer's Disease and Tg2576 Mice; Implications for Glial Cells. Brain Pathol 2008; 18(4):548-61.

 # 29. Bertram, L., Schjeide, BM., Hooli, B., Mullin, K., Hiltunen, M., Soininen, H., ***Ingelsson, M.,*** *Lannfelt, L., Blacker, D., MD, Tanzi, R. No association between CALHM1 and Alzheimer's disease risk. Cell 2008; 135:993-4.*

30. Philipson, O., Hammarström, P., Nilsson, K.P.R., Portelius, E., Olofsson, T., **Ingelsson, M.**, Hyman, B.T., Blennow, K., Lannfelt, L., Kalimo, H., Nilsson, L.N.G. The Highly Insoluble State of A-beta in Alzheimer's Disease Brain is Recreated in APP Transgenic Mice with the Arctic Mutation. Neurobiol Aging 2009; 30:1393-1405.

 # 31. Näsström, T., Wahlberg, T., Karlsson, M., Nikolajeff, F., Lannfelt, L., ***Ingelsson, M.****, Bergström J. The lipid peroxidation metabolite 4–oxo–2-nonenal cross-links alpha-synuclein and causes rapid formation of stable oligomers. Biochem Biophys Res Commun 2009;23:872-6.*

32. Skoglund, L., Brundin, RM., Olofsson, T., Kalimo, H., Ingvast, S., Blom, E., Giedraitis, V., **Ingelsson, M.,** Lannfelt, L., Basun, H., Glaser, A. Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation, Neurogenetics 2009; 10(1):27-34.

33. Blom, ES., Giedraitis, V., Fukumoto, H., Zetterberg, H., Blennow, K., Hyman, BT., Irizarry, MC., Wahlund, LO., Lannfelt, L., **Ingelsson, M**. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOEε4/ε4 genotype. Dement Ger Cogn Disord 2009; 27(5):458-64.

34. Skoglund, L., Ingvast, S., Matsui, T., Brundin, RM., Giedraitis, V., Freeman, SH., Growdon, JH., Frosch, MP., Hyman, BT., Lannfelt, L., **Ingelsson, M.**, Glaser,.A. No evidence of *PGRN* or *MAPT* gene dosage alterations in a collection of patients with frontotemporal lobar degeneration. Dement Ger Cogn Disord 2009; 28(5):471-5.

35. Fukumoto, N., Fujii1, T., Combarros, O., Kamboh, MI., Tsai, SJ., Matsushita, S., Nacnias, B., Comings, DE., Arboleda, H., **Ingelsson, M.,** Hyman, BT., Akatsu, H., Grupe, A., Nishimura1, AL., Zatz, M., Mattila1, KM., Got, Y., Asada, T., Nakamura, S., Kunugi, H. Sexually dimorphic effect of the *BDNF* Val66Met polymorphism on susceptibility to Alzheimer's disease: new data and meta-analysis. Am J Med Genet 2010; 153B(1):235-42.

36. Wirths, O., Bethge, T., Marcello, A., Harmeier, A., Jawahr, S., Lucassen, P., Multhaup, G., Brody, D., Esparza, T., **Ingelsson, M**., Kalimo, H., Lannfelt, L., Bayer, T. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm 2010; 117(1):85-96.

37. Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA, Buee L, Castellazzi M, Cepok S, Comabella M, Constantinescu CS, Deisenhammer F, Deniz G, Erten G, Espiño M, Fainardi E, Franciotta D, Freedman M, Giedraitis V, Gilhus NE, Giovannoni G, Glabinski A, Grieb P, Hartung HP, Hemmer B, Herukka SK, Hintzen R, **Ingelsson M**, Jackson S, Jacobsen S, Jafari N, Jalosinski M, Jarius S, Kapaki E, Kieseier BC, Koel-Simmelink MJ, Kornhuber J, Kuhle J, Kurzepa J, Lalive P, Lannfelt L, Lehmensiek V, Lewczuk P, Livrea P, Marnetto F, Martino D, Menge T, Norgren N, Papuc E, Paraskevas GP, Pirttilä T, Rajda C, Rejdak K, Ricny J, Ripova D, Rosengren L, Ruggieri M, Schraen S, Shaw G, Sindic C, Siva A, Stigbrand T, Stonebridge I, Topcular B, Trojano M, Tumani H, Twaalfhoven HA, Vécsei L, Van Pesch V, Vanderstichele H, Vedeler C, Verbeek MM, Villar LM, Weissert R, Wildemann B, Yang C, Yao K, Teunissen C. Neurofilament ELISA validation. J Immun Methods 2010; 352:23-31.

38. Giedraitis, V., Glaser, A., Sarajärvi, T., Brundin, RM, Degerman Gunnarsson, M., Tanzi, RE, Helisalmi, S., Pirttilä, T., Kilander, L., Lannfelt, L., Soininen, H., Bertram, L., **Ingelsson, M**., Hiltunen, M. The *CALHM1 P86L* polymorphism does not

38. Giedraitis, V., Glaser, A., Sarajärvi, T., Brundin, RM, Degerman Gunnarsson, M., Tanzi, RE, Helisalmi, S., Pirttilä, T., Kilander, L., Lannfelt, L., Soininen, H., Bertram, L., **Ingelsson, M**., Hiltunen, M. The *CALHM1 P86L* polymorphism does not alter the levels of amyloid-beta, total tau or phospho-tau in cerebrospinal fluid. Neurosci Lett 2010; 469(2):265-7.

39. Sehlin D, Söllvander S, Paulie S, Brundin R, **Ingelsson M**, Lannfelt L, Pettersson FE, Englund H. Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs. J Alzheimers Dis 2010; 21(4):1295–1301.

40. Faux, NG., Ritchie, CW, Gunn A., Rembach, A., Tsatsanis, A., Bedo, J., Harrison, J., Lannfelt, L., Blennow, K., Zetterberg, H., **Ingelsson, M.**, Masters, CL., Tanzi, RE., Cummings, JL., Herd, CM., Bush, AI., PBT2 rapidly improves cognition in Alzheimer[1]s disease: additional phase 2 analyses. J Alzheimers Dis 2010; 20 (2):509-16.

41. Soscia, SJ., Kirby, JE., Washicosky, KJ., Tucker, SM., **Ingelsson, M**., Hyman, BT., Burton, MA, Goldstein, LE, Duong, S., Tanzi, RE., Moir, RD. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 2010; 5:3:e9505.

42. Sundelöf, J., Sundström, J., Hansson, O., Eriksdotter-Jönhagen, M., Giedraitis, V., Larsson, A., Degerman-Gunnarsson, M., **Ingelsson, M**., Minthon, L., Blennow, K., Kilander, L., Basun, H., Lannfelt, L. Cystatin C levels are positively correlated with both Aβ42 and Tau Levels in CSF in subjects with Alzheimer's Disease, Mild Cognitive Impairment and Healthy Controls. J Alzheimers Dis 2010 1; 21(2):471-8.
43. Beyer, A-S., von Einem, B., Schwanzar, D., Keller, IE., Hellrung, A., Thal, DR., **Ingelsson, M.**, Makarova, A., Deng, M., Chhabra, ES., Pröpper, C., Böckers, TM., Hyman, BT., von Arnim, CAF. Engulfment adaptor PTB domain containing 1 interacts with and affects processing of the amyloid-beta precursor protein. Neurobiol Aging 2012; 33(4):732-43
44. Lambert, J-C., Sleegers, K., **Ingelsson, M**., Beecham, G.W., Hiltunen, M., Combarros, O., Bullido, MJ., Brouwers, N., Bettens, K., Berr, C., Pasquier, F., Richard, F. DeKosky, ST., Hannequin, D., Haines, JL., Fiévet, N., Dartigues, J-F., Tzourio, C., Engelborghs, S., Arosio, B., Coto, E., De Deyn, P., Del Zompo, M., Mateo, I., Epelbaum, J., Michaud Schjeide, B-M.M., Frank-Garcia, A., 25, Giedraitis, V., Helisalmi, S., Porcellini, E., Pilotto, A., Forti, P., Ferri, R., Zelenika, D., Lathrop, M., Scarpini, E., Siciliano, G., Solfrizzi, V., Sorbi, S., Spaletta, G., Ravaglia, G., Valdivieso, F., Vepsäläinen, D., Alvarez, V., Bosco, P., Tanzi, R., lo Mancuso, M., Panza, F., Nacmias, B., Bossù, P., Hanon, O., Piccardi, P., Annoni, G., Mann, D., Marambaud, P., Seripa, D., Galimberti, D., Bertram, L., Lendon, C., Lannfelt, L., Licastro, F., Campion, D., Pericak-Vance, M., Soininen, H., Van Broeckhoven, C., Alpérovitch, A., Ilyas Kamboh, M., Amouyel1, P. The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. J Alzh Dis. 2010; 22(1):247-55.

 # 45. Sundelöf, J., Sundström, J., Hansson, O., Eriksdotter-Jönhagen, M., Giedraitis, V., Larsson, A., Degerman-Gunnarsson, M., Ingelsson, M.**, Minthon, L., Blennow, K., Kilander, L., Basun, H., Lannfelt, L. Higher Cathepsin B Levels in Plasma in Alzheimer´s Disease Compared to Healthy Controls. J Alzh Dis. 2010; 22(4):1223-30.**

46. Wirths, O., Erck, C., Martens, H., Harmeier, A., Geumann, C., Jawahr, S., Kumar, S., Multhaup, G., Walter, J., **Ingelsson, M**., Degerman-Gunnarsson, M., Kalimo, H., The Netherlands Brain Bank, Lannfelt, L., Bayer, T. Identification of low molecular weight pyroglutamate Abeta oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem. 2010; 285(53):41517-24.

47. Skoglund, L., Matsui, T., Freeman, SH., Wallin, A., Blom, E., Frosch, MP., Growdon, JH., Hyman, BT., Lannfelt, L., **Ingelsson, M**., Glaser, A. Novel Progranulin Mutation Detected in Two Patients With FTLD. Alzheimer Dis Assoc Disord. 2011; 25(2):173-8.

Mutation Detected in Two Patients With FTLD. Alzheimer Dis Assoc Disord. 2011; 25(2):173-8.

48. Näsström, T., Wahlberg, T, Barbu, M., Karlsson, M., Nikolajeff, F., Kasrayan, A., Ekenberg, M., Lannfelt, L., **Ingelsson, M.** Bergström, J. The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of alpha-synuclein oligomers with distinct biochemical, morphological and functional properties. Free Rad Biol Med 2011; 50(3):428-37.

49. Blom ES., Wang, Y., Skoglund, L., Hansson , A., Ubaldi , M., Lourdusamy , A., Sommer , W., Mielke, M., Hyman , BT., Heilig , M., Lannfelt , L., Nilsson , LNG., **Ingelsson, M**. Increased mRNA levels of *TCF7L2* and *MYC* of the Wnt pathway in tgAPP-ArcSwe mice and in Alzheimer's disease brain. Int J Alzh Dis 2011; 22:936580.

50. Welander, H., Bontha, SV., Näsström, T., Karlsson, M., Nikolajeff, F., Danzer, K., Kalimo, H., Lannfelt, L., **Ingelsson, M**., Bergström, J. Gelsolin co-occurs with Lewy bodies and accelerates α-synuclein aggregation *in vitro*. Biochem Biophys Res Commun 2011; 19;412(1):32-8.

51. Näsström, T., Gonçalves, S., Sahlin, C., Nordström, E., Screpanti Sundquist, V., Lannfelt, L., Bergström, J., Outeiro, T.F., **Ingelsson, M.** Antibodies against alpha-synuclein reduce oligomerization in living cells. PLoS One 2011; 6(10):e27230.

 # 52. Philipson, O., Lord, A., Lalowski, M., Soliymani, R., Baumann, M., Thyberg, J., Bogdanovic, N., Olofsson, T., Tjernberg, L., Ingelsson, M., Lannfelt, L., Kalimo, H., Nilsson, LNG. The Arctic *AβPP* mutation results in distinct plaques and accumulation of N- and C-truncated Aβ. Neurobiol Aging 2012; 33(5):1010.e1-1010.e13.

53. Forsberg, LA., Rasi, C., Razzaghian, HR., Pakalapati, G., Thibeault, C., Waite, L., Ronowicz, A., Wineinger, NE., Tiwari, HE., Boomsma, D., Westerman, MP., Harris, J., Essand, M., Eriksson, F., ADVANCE cohort, Strachan, E., O'Hanlon, TP., Rider, LG., Miller, FW., Giedraitis, V., Lannfelt, L., **Ingelsson, M.,** Piotrowski, A., Pedersen, NL., Absher, D., Dumanski, JP. Accumulation of structural variation with age in nuclear genome of normal human blood cells *in vivo*. Am J Hum Genet 2012; 10;90(2):217-28.

54. Sehlin, D., Englund, H., Simu, B., Karlsson, M., **Ingelsson, M.**, Nikolajeff, F., Lannfelt, L., Ekholm Pettersson, F. Large aggregates are the major soluble Abeta species in AD brain fractionated with density gradient ultracentrifugation. PLoS One 2012; 7(2):e32014.

55. Diógenes, MJ., Dias, RA., Rombo, DM., Vicente Miranda, H., Maiolino, F., Guerreiro, P., Näsström, T., Franquelim, HG., Oliveira, LM., Castanho, M., Lannfelt, L., Bergström, J., **Ingelsson**, **M.**, Quintas, A., Sebastião, AM., Lopes, LV, Outeiro, TF. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 2012; 32(34):11750-62.

56. Lambert, JC., Grenier-Boley, B., Harold, D., Zelenika, D., Chouraki, V., Kamatani, Y., Sleegers, K., Ikram, A., Hiltunen, M., Reitz, C., Mateo, I., Feulner, T., Bullido, M., Galimberti, D., Concari, L., Alvarez, V., Sims, R., Gerrish, A., Chapman, J., Deniz-Naranjo, C., Solfrizzi, V., Sorbi, S., Arosio, B., Spalletta, G., Siciliano, G., Epelbaum, J., Hannequin, H., Dartigues, J-F., Tzourio, C., Berr, C., Schrijvers, EMC., Rogers, R., Tosto, G., Pasquier, F., Bettens, K., Van Cauwenberghe, C., Fratiglioni, L., Graff, C., Delepine, M., EADI consortium, GERAD consortium, Ferri, R., Reynolds, CA., Lannfelt, L., **Ingelsson, M.**, Prince, JA., Chillotti, C., Greco, A., Seripa, D., Boland, A., Mancuso, M., Bossù, P., Annoni, G., Nacmias, B., Bosco, P., Panza, F., Sanchez-Garcia, F., Del Zompo, M., Coto, E., Owen, M., O'Donovan, M., Valdivieso, F., Caffara, P., Scarpini, E., Combarros, O., Buée, L., Campion, D., Soininen, H., Breteler, M., Riemenschneider, M., Van Broeckhoven, C., Alpérovitch, A., Lathrop, M., Trégouët, D-A., Williams, J., Amouyel, P. Genome-wide haplotype association study identifies the *FRMD4A* gene as a risk locus for Alzheimer's disease.

Soininen, H., Breteler, M., Riemenschneider, M., Van Broeckhoven, C., Alpérovitch, A., Lathrop, M., Trégouët, D-A., Williams, J., Amouyel, P. Genome-wide haplotype association study identifies the *FRMD4A* gene as a risk locus for Alzheimer's disease. Nature Genet 2013;18(4):461-70.

 # 57. Fagerqvist, T., Lindström, V., Nordström, E., Lord, A., Tucker, SME., Sahlin, C., Kasrayan, A., Andersson, J., Welander, H., Näsström, T., Holmquist, M., Schell, H., Kahle, P., Kalimo, H., Möller, C., Gellerfors, P., Lannfelt, L., Bergström, J., Ingelsson, M. **Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation. J Neurochem 2013; 126(1):131-44.**

58. Fagerqvist, T., Näsström, T., Sahlin, C., Tucker, S., Lindström, V., Karlsson, M., Nikolajeff, F., Schell, H., Kahle, P., Kasrayan, A., Ekenberg, M., Lannfelt, L., **Ingelsson, M**., Bergström J. Off-pathway α-synuclein oligomers seem to alter α-synuclein turnover in a cell model but lack seeding capability *in vivo*. Amyloid 2013; 20(4):233-44.

59. Rubio-Moscardo, F., Seto-Salvia, N., Pera, M., Bosch-Morato, M., Plata, C., Belbin, O., Gene, G., Dols-Icardo, O., Ingelsson, M., Helisalmi, S., Soininen, H., Hiltunen, M., Giedraitis, V., Lannfelt, L., Frank, A., Bullido, M.J., Combarros, O., Sanchez-Juan, P., Boada, M., Tarraga, L., Pastor, P., Perez-Tur, J., Baquero, M., Molinuevo, J.L., Sanchez-Valle, R., Fuentes-Prior, P., Fortea, J., Blesa, R., Munoz, F.J., Lleo, A., Valverde, M.A., and Clarimon, J. (2013). Rare variants in calcium homeostasis modulator 1 (CALHM1) found in early onset Alzheimer's disease patients alter calcium homeostasis. PloS one *8*, e74203.

60. Kalimo, H., Lalowski, M., Bogdanovic, N., Philipson, O., Bird, T.D., Nochlin, D., Schellenberg, G.D., Brundin, RM, Olofsson, T., Lalowski, M., Baumann, M., Wirths, O., Bayer, T., Nilsson, L.N.G., Basun, H., Lannfelt, L. **Ingelsson, M**. The *Arctic APP* mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Ab. Acta Neuropathol Commun 2013; 1(1):60.

61. Degerman Gunnarsson, M., Lannfelt, L., **Ingelsson, M.,** Basun, H., Kilander, L. High tau levels in cerebrospinal fluid predict poor prognosis in Alzheimer's disease. Dement Geriatr Cogn Disord 2013; 37(3-4):196-206.

62. Antonios, G., Saiepour, N. Bouter, Y. Richard, B., Paetau, A., Verkkoniemi, A., Lannfelt, L., **Ingelsson, M.,** Kovacs, GG., Pillot, T., Wirths, O., Bayer, TA. N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody. Acta Neuropathol Commun 2013; 1(1):56.

63. Westman, G., Lidehall, A-K., Magnusson, P., **Ingelsson, M**., Kilander, L., Lannfelt, L., Korsgren, O., Eriksson, B-M. Decreased proportion of cytomegalovirus specific CD8 T-cells but no signs of general immunosenescence in Alzheimer's disease. PLoS One 2013;8(10):e77921.

64. Reinert, J., Martens, H., Huettenrauch, M., Lannfelt, L., **Ingelsson, M.,** Paetau, A.,Verkkoniemi, A., Bayer, TA., Wirths, O. Ab38 in the brains of sporadic and familial Alzheimer's disease and transgenic mouse models. J Alzh Dis 2014 ;39(4):871-81.

65. Lambert, J-C., …**Ingelsson, M**., …Amouyel, P. (182 authors) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013 Oct 27. doi: 10.1038/ng.2802.

66. Musunuri, S., Wetterhall, M., **Ingelsson, M.**, Lannfelt, L., Artemenko, K., Bergquist, J., Kultima, K., Shevchenko, G. Quantification of brain proteome in Alzheimer's disease using multiplexed mass spectrometry: Focus on biomarkers. J Proteome Res. 2014 2014 Apr 4;13(4):2056-68. doi: 10.1021/pr401202d. Epub 2014

Bergquist, J., Kultima, K., Shevchenko, G. Quantification of brain proteome in Alzheimer's disease using multiplexed mass spectrometry: Focus on biomarkers. J Proteome Res. 2014 2014 Apr 4;13(4):2056-68. doi: 10.1021/pr401202d. Epub 2014 Mar 19

67. Escott-Price, V.,…**Ingelsson, M**.,…Williams, J. (188 authors) Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. PLoS One. 2014 Jun 12;9(6):e94661.

68. Guzmán, EA., Bouter, Y., Richard, BC., Lannfelt, L., **Ingelsson, M.,** Paetau, A., Verkkoniemi, A., Wirths, O., Bayer, TA. Abundance of $A\beta_{5-x}$ in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer´s Disease. Mol Neurodegener. 2014 Apr 2;9:13

69. Westman, G., Berglund, D., Widén, J., **Ingelsson, M**., Korsgren, O., Lannfelt, L., Sehlin, D., Lidehall A-K., Eriksson, B-M. Increased Inflammatory Response in Cytomegalovirus Seropositive Patients with Alzheimer's Disease. PLoS One 2014 May 7;9(5):e96779.

70. Pannee J, Törnqvist U, Westerlund A, **Ingelsson M,** Lannfelt L, Brinkmalm G, Persson R, Gobom J, Svensson J, Johansson P, Zetterberg H, Blennow K, Portelius E. The amyloid-β degradation pattern in plasma - a possible tool for clinical trials in Alzheimer's disease. Neurosci Lett. 2014 Jun 24;573:7-12.

71. Lindström, V., Fagerqvist, T., Nordström, E., Lord, A., Tucker, S., Andersson, J., Johannesson, M., Schell, H., Kahle, P., Möller, C., Gellerfors, P., Bergström J., Lannfelt, L., **Ingelsson, M.** Reduced pathology in transgenic mice following immunotherapy with oligomer/protofibril selective α-synuclein antibodies. Neurobiol Dis. 2014 Sep;69:134-43.

72. Watts, JC., Condello, C., Stöhr, J., Oehler, A., Lee, J., DeArmond, SJ., Lannfelt, L., **Ingelsson, M.**, Giles, K., Prusiner, SB. The Arctic Alzheimer's disease mutation enciphers a distinct strain of Aβ prions. Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10323-8.

73. Kvartsberg, H., Duits, FH., **Ingelsson, M**., Andreasen N., Öhrfelt, A., Andersson, K., Brinkmalm, G., Lannfelt, L., Minthon, L., Hansson, O., Andreasson, U., Teunissen, CE., Scheltens, P., Van der Flier, WM., Zetterberg, H., Portelius, E., Blennow, K. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer´s disease. Alzh Dem 2014 Dec 19. pii: S1552-5260(14)02863-5.

74. International Genomics of Alzheimer's Disease Consortium (IGAP). Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimers Dement. 2014 Dec 20. pii: S1552-5260(14)02492-3.

75. Dumanski, JP., Rasi, C., Lönn, M., Davies, H., **Ingelsson, M**., Giedraitis, V., Magnusson, P., Lindgren, CM:, Morris, AP., Cesarini, D., Johannesson, M., Tiensuu Jansson, E., Lind, L., Pedersen, NP., Ingelsson, E., Forsberg, LA. Mutagenesis. Smoking is associated with mosaic loss of chromosome Y. Science 2015 Jan 2;347(6217):81-3.

76. Musunuri, S., Kultima, K., Richard, BC., **Ingelsson, M.,** Lannfelt, L., Bergquist, J., Shevchenko, G. Micellar extraction possesses a new advantage for the analysis of Alzheimer's disease brain proteome. Anal Bioanal Chem 2015 Feb;407(4):1041-57.

77. Oskarsson, M., Paulsson, JF., Schultz, SW., **Ingelsson, M.,** Westermark, P., Westermark, GT *In vivo* seeding and cross-seeding of localized amyloidosis: A molecular link between type 2 diabetes and Alzheimer's disease. Am J Pathol 2015 Mar;185(3):834-46

78. Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert JC, Chung J, Naj AC, Kunkle BW, Wang LS, Bis JC, Bellenguez C, Harold D, Lunetta KL, Destefano AL,

78. Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert JC, Chung J, Naj AC, Kunkle BW, Wang LS, Bis JC, Bellenguez C, Harold D, Lunetta KL, Destefano AL, Grenier-Boley B, Sims R, Beecham GW, Smith AV, Chouraki V, Hamilton-Nelson KL, Ikram MA, Fievet N, Denning N, Martin ER, Schmidt H, Kamatani Y, Dunstan ML, Valladares O, Laza AR, Zelenika D, Ramirez A, Foroud TM, Choi SH, Boland A, Becker T, Kukull WA, van der Lee SJ, Pasquier F, Cruchaga C, Beekly D, Fitzpatrick AL, Hanon O, Gill M, Barber R, Gudnason V, Campion D, Love S, Bennett DA, Amin N, Berr C, Tsolaki M, Buxbaum JD, Lopez OL, Deramecourt V, Fox NC, Cantwell LB, Tárraga L, Dufouil C, Hardy J, Crane PK, Eiriksdottir G, Hannequin D, Clarke R, Evans D, Mosley TH Jr, Letenneur L, Brayne C, Maier W, De Jager P, Emilsson V, Dartigues JF, Hampel H, Kamboh MI, de Bruijn RF, Tzourio C, Pastor P, Larson EB, Rotter JI, O'Donovan MC, Montine TJ, Nalls MA, Mead S, Reiman EM, Jonsson PV, Holmes C, St George-Hyslop PH, Boada M, Passmore P, Wendland JR, Schmidt R, Morgan K, Winslow AR, Powell JF, Carasquillo M, Younkin SG, Jakobsdóttir J, Kauwe JS, Wilhelmsen KC, Rujescu D, Nöthen MM, Hofman A, Jones L; **IGAP Consortium**, Haines JL, Psaty BM, Van Broeckhoven C, Holmans P, Launer LJ, Mayeux R, Lathrop M, Goate AM, Escott-Price V, Seshadri S, Pericak-Vance MA, Amouyel P, Williams J, van Duijn CM, Schellenberg GD, Farrer LA. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psych. 2015 Mar 17. doi: 10.1038/mp.2015.23. [Epub ahead of print]

79. Quantitative Interaction Proteomics of Neurodegenerative Disease Proteins. Hosp F, Vossfeldt H, Heinig M, Vasiljevic D, Arumughan A, Wyler E; the Genetic and Environmental Risk for Alzheimer's Disease (GERAD1) Consortium, Landthaler M, Hubner N, Wanker EE, Lannfelt L, **Ingelsson M**, Lalowski M, Voigt A, Selbach M. Cell Rep. 2015 May 6. pii: S2211-1247

80. Cai, Y., Lendel, C., Österlund, L., Lannfelt, L., **Ingelsson, M.**, Nikolajeff, F., Karlsson, M., Bergström, J. Changes in secondary structure of α-syn during oligomerization induced by reactive aldehydes. Biochem Biophys Res Commun. 2015 Jun 27. pii: S0006-291X(15)30212-6. doi: 10.1016/j.bbrc.2015.06.154. [Epub ahead of print].

Other peer-reviewed publications

1. **Ingelsson, M.**, Hyman, B.T., Disordered proteins in dementia. Ann Med 2002; 34:1-13.

2. **Ingelsson, M.**, Fukumoto, H. Newell, K., Hyman, BT., Irizarry, MC. Lack of correlation between biochemical and neuropathological amyloid measures in the Alzheimer brain. Ana Aslan International Academy of Aging 2003; 191-8.

3. Klucken, J., McLean, P.J. Gomez-Tortosa, E., **Ingelsson, M.**, Hyman, B.T. Neuritic alterations and neural system dysfunction in Alzheimer´s disease and Lewy body dementia. Neurochem Res 2003; 11:1683-91.

4. Hyman, B.T., Augustinack, J.C., **Ingelsson, M.**, Transcriptional and conformational changes of the tau molecule in Alzheimer's Disease. Biochim Biophis Acta 2005; 1739 (2-3):150-7.

5. **Ingelsson, M.**, Nilsson, L., Basun, H., Aquilonius, S-M., Lannfelt, L. Conformationally altered proteins cause neurodegenerative disorders. Läkartidningen 2005; 0547 (102):3542-51 (Swedish).

6. **Ingelsson, M.**, Hyman, B.T. The molecular basis of Alzheimer's disease. Chapter 16, p.p. 241-55. In: Molecular Neurology 2007. Elsevier Academic Press, Burlington, MA. Editor: Stephen G. Waxman.

7. Kilander, L., Landahl, P. **Ingelsson, M**. O, min man- om den förbryllande sjukdomen frontallobsdemens; Gothia 2009.

7. Kilander, L., Landahl, P. **Ingelsson, M**. O, min man- om den förbryllande sjukdomen frontallobsdemens; Gothia 2009.

8. **Ingelsson, M**., Basun, H., Ekholm Pettersson, F., Kilander, L., Nilsson, LNG., Lannfelt, L. Alzheimer's disease- rare mutations aim toward future treatment. Läkartidningen 2009; 20:1396-1400 (Swedish)..

9. **Ingelsson, M.,** Fagius, J. Synpunkter på åldrandets neurologi. In: Neurologi, 5:th edition, Stockholm, Liber, 2013.

10. Lindström, V., Ihse, E., Fagerqvist, T., Bergström, J., Nordström, E., Möller, C., Lannfelt, L., **Ingelsson, M.** Immunotherapy targeting α-synuclein – with relevance for future treatment of Parkinson's disease and other Lewy body disorders. Immunotherapy 2014; 6(2):141-53.

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

1. **Ingelsson, M.**, Lannfelt, L., Tau in fibroblasts with and without the Swedish APP 670/671 mutation. Neurobiology of Aging, 1996, 17 (4S), S 101.

2. **Ingelsson, M.**, Benedikz, E., Karlsson, E., Lannfelt, L., Evidence for the presence of the microtubule-associated protein tau in human plasma. Poster/ Society for Neuroscience 27th Annual Meeting, New Orleans October 25-30 1997.

 # 3. Forsell, C., Froelich, S., Axelman, K., Vestling, M., Cowburn, R.F., Lilius, L., Johnston, J.A., Engvall, B., Dahlkild, Å., Ingelsson, M.**, St George-Hyslop, P.H., Lannfelt, L., A novel pathogenic mutation (Leu262Phe) found in the Presenilin 1 gene in early-onset Alzheimer's Disease. Fondation IPSEN, Présénilines et Maladie D'Alzheimer, Paris April 28 1997.**

4. **Ingelsson, M.**, Blomberg, M., Benedikz, E., Karlsson, E., Vanmechelen, E., Lannfelt, L. Evidence for the presence of tau-like proteins in human plasma. Neurobiology of Aging, 1998, 19 (4S), S 58.

5. **Ingelsson, M.**, Froelich, S., Lilius, L., Wahlund, L.O., Lannfelt, L., Investigation of a dinucleotide repeat polymorphism in the tau gene in a clinical population with frontotemporal dementia. Colloques médecine et recherche; Poster/ Paris April 12 1999.

6. **Ingelsson, M.**, Froelich Fabre, S., Lilius, L., Andersen, C., Viitanen, M., Wahlund, L.O., Lannfelt, L., No association with tau polymorphisms in a clinical population with frontotemporal dementia. Poster/ Society for Neuroscience 29th Annual Meeting, Miami October 23-29 1999.

7. Lannfelt, L., Froelich Fabre, S., Lilius, L., Andersen, C., Viitanen, M., Almkvist, O., Wahlund, L.-O., **Ingelsson, M.** Increased risk for frontotemporal lobar degeneration through interaction between the tau intron 9 polymorphism and APOE *e*4. Talk/ Society for Neuroscience 30th Annual Meeting, New Orleans November 4-9 2000

 # 8. Ingelsson, M.**, Froelich Fabre, S. Volkman, I., Basun, H., Näslund, J., Lannfelt, L., Bogdanovic, N.**
Tau with three and four microtubule-binding repeats in human brain of Alzheimer's disease and frontotemporal dementia. Poster/ World Alzheimer Congress, Washington D.C. 2000
9. **Ingelsson, M.**, Froelich Fabre, S, Volkmann, I., Sundström, E., Näslund, J., Lannfelt, L., Bogdanovic, N. Three microtubule-binding repeat tau (3R tau) are the major tau isoforms in Alzheimer neuropathology. Poster/ Society for Neuroscience 31st Annual Meeting, San Diego November 10-15 2001

10. Fukumoto, H., Newell, K., **Ingelsson, M.,** Hyman, BT., Irizarry, MC.

31st Annual Meeting, San Diego November 10-15 2001

10. Fukumoto, H., Newell, K., **Ingelsson, M.,** Hyman, BT., Irizarry, MC. Biochemical measures in Alzheimer brain. Correlation of synaptophysin loss but not Ab levels with duration of illness. Massachusetts Alzheimer's Disease Research Center 15th Annual Scientific Poster Session 2002

11. **Ingelsson, M.**, Dombeck, D.A., Kasischke, KA., Vishwasrao, H.D., Hyman, B.T. Webb, W.W. Second Harmonic Imaging of Axonal Microtubules in the Hippocampus. Poster/ Society for Neuroscience 32d Annual Meeting, Orlando 2002

12. **Ingelsson M.**, Fukumoto H, Newell K, Hyman BT, Irizarry MC. Biochemical and neuropathological measures in Alzheimer brain: correlation of synaptophysin loss but not Ab levels with duration of disease. Alzheimer Association 2002 (Stockholm). Neurobiol Aging; 23 (1529):S416.

13. Huang, W., Dobberfuhl, A., **Ingelsson, M.**, Filippopoulos, T., Grosskreutz, C. Detection of gene expression changes of caspase 8 and Thy1 in rat retinal ganglion cells after optic nerve crush using laser capture microdissection with real-time PCR. Poster/ The association for research in vision and ophtalmology. Fort Lauderdale 2003

14. Lawler, S., **Ingelsson, M.**, Augustinack, J., Saeki, Y., Hyman, B., Bhide, P.G., Chiocca, E.A. Wade-Martins, R. Examination of tau splicing using an HSV amplicon expression system. Poster/ Society for Neuroscience 33rd Annual Meeting, New Orleans 2003

15. **Ingelsson, M.**, Cantuti-Castelvetri, I., Augustinack, J.C., Vanderburg, C.R., Growdon, J.H. Frosch, M.P. Irizarry, M.C., Standaert, D.G., Hyman, B.T. Quantitative PCR-analysis of tau with three and four microtubule-binding repeat regions from Alzheimer temporal lobe tissues. Talk/ Society for Neuroscience 33rd Annual Meeting, New Orleans 2003

16. Lawler, S., **Ingelsson, M.**, Augustinack, J., Saeki, Y., Hyman, B., Chiocca, E.A. Wade-Martins, R. Examination of the Pathological Mechanism of the Microtubule Associated Protein Tau Using an HSV Amplicon Based Neuronal Gene Delivery System. Poster/ American Society of Gene Therapy, 6th Annual Meeting (Washington D.C.) June 4-8 2003

17. Dombeck, DA., Kasischke KA., Vishwasrao HD., **Ingelsson M.**, Hyman, B.T, Webb, W.W. Second harmonic imaging of axonal microtubules in the hippocampus. 2003 Biophysical Society meeting, San Antonio 2003

18. Levene, M.J., Dombeck, D.A., Williams, R.M., Skoch, J., Hickey, G.A., Kasischke, K.A., Molloy, R.P., **Ingelsson, M.**, Stern, E.A., Klucken, J., Bacskai, B.J., Zipfel, W.R., Hyman, B.T., Webb, W.W. In vivo multiphoton microscopy of deep tissue with gradient index lenses. Photonics West. San José 2004 and published in Proc. SPIE Vol. 5323, p. 291-296, Multiphoton Microscopy in the Biomedical Sciences IV; Ammasi Periasamy, Peter T. So; Eds.

19. Kim, M.J., Bertram, L., **Ingelsson, M.**, Lu, A., Hyman, B.T., Tanzi, R.E. Functional Analysis of the Insulin Degrading Enzyme in Genetically-Associated AD Families. Poster/ Alzheimer Association 2004 (Philadelphia)

20. **Ingelsson, M.**, Cantuti-Castelvetri, I., Ramasamy, K., Orne, J., Augustinack, J.C., Vanderburg, C.R., Growdon, J.H., Frosch, M.P., Irizarry, M.C., Standaert, D.G., Hyman, B.T. Analysis of gene expression in the Alzheimer's disease brain. Poster/ Alzheimer Association 2004 (Philadelphia)

21. SantaCruz, K.S., Lewis, J., Paulson, J., **Ingelsson, M.**, Kotilinek, L., Forster, C., Guimaraes, A., Mariash, A., Hyman, B.T., Hutton, M., Ashe, K.H. Cognitive impairment in transgenic mice with abnormal intraneuronal tau phosphorylation but little silver positive neurofibrillary pathology. J Neuropathol Exp Neurol 2004, 63 (5), 554.

22. Cantuti-Castelvetri, I., **Ingelsson, M.**, Klucken, J., Ramasamy, K., Hyman, B.T., Standaert, D.G. Dysregulation of chaperone proteins in Dementia with Lewy bodies.

22. Cantuti-Castelvetri, I., **Ingelsson, M.**, Klucken, J., Ramasamy, K., Hyman, B.T., Standaert, D.G. Dysregulation of chaperone proteins in Dementia with Lewy bodies. Poster/ The Movement Disorder Society 2004 (Rome)

23. Giedraitis, V., Kilander, L., Degerman-Gunnarsson, M., Sundelöf, J., Berglund, L., Blom, E., Ingelsson, M., Glaser, A. and Lannfelt, L. Genetic analysis of Alzheimer's disease in the ULSAM cohort. Poster/ Wallenberg Consortium Nord Annual Conference 2005

24. Giedraitis, V., Sundelöf, J., Irizarry, M.C., Degermann Gunnarsson, M., Kilander, L., Glaser, A., **Ingelsson, M.,** Hyman, B.T., Basun, H. Lannfelt, L. Regulation of Aβ levels in human plasma. Poster/ Wallenberg Consortium Nord Annual Conference 2005

25. Matsui, T., Ramasamy, K., **Ingelsson, M.**, Conrad, C., Frosch, M.P., Irizarry, M.C., Yuan, J., Hyman, B.T. Elevated mRNA Expression of Caspase-7 and 8 are Associated with Insoluble Aβ42 Levels in AD Brain. Poster/ Society for Neuroscience 35th Annual Meeting, Washington D.C. 2005

26. Lannfelt, L., Skoglund, L., Glaser, A., Kilander, L., Brundin, R., Basun, H., **Ingelsson, M**. Advances in Genetics of Frontotemporal Dementia. Poster/ Annual meeting for the International Psychiatric Association, Stockholm 2005

27. **Ingelsson, M.**, Russ, C., Ramasamy, K., Orne, J., Skoglund, L., Raju, S., Growdon, J.H., Frosch, M.P., Ghetti, B., Brown Jr., R.H., Irizarry, M., Hyman, B.T. Characterization of tau in human frontal cortex on a neuropathological cohort of tauopathies. Poster/ Society for Neuroscience 35th Annual Meeting, Washington D.C. 2005

28. Conrad, C., Zhu, J., Conrad, C., **Ingelsson, M.**, Church, C., Hyman, B. Single Molecule Exon and Haplotype Profiling of Tau Gene Expression in Alzheimer's disease. Poster/ Society for Neuroscience 35th Annual Meeting, Washington D.C. 2005

29. Zhang, X., O'Callaghan, P., Hong, Y., **Ingelsson, M.,** Hyman, BT, Li, J-P., Lindahl, U., Lannfelt, L.Comparative analysis of heparan sulfate co-localization with Ab40 and Ab42 in different Ab deposits in APP transgenic and Alzheimer's disease brain tissue. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Madrid 2006

30. Sundelöf, J., Giedraitis, V., Irizarry, MC. Hyman, BT., Sundström, J., Ingelsson, E., Rönnemaa, E., Degerman-Gunnarsson, M., Basun, H., **Ingelsson, M.,** Kilander, L., Lannfelt, L. Plasma amyloid-b protein (Ab) in the Uppsala Longitudinal Study of Adult Men (ULSAM). Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Madrid 2006

31. Giedraitis, V., Gårevik, N., Sundelöf, J., Irizarry, MC., **Ingelsson, M.,** Lannfelt, L. Amyloid beta levels in plasma and CSF are correlated in healthy individuals. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Madrid 2006

32. Blom, E., Sommer, W., Heilig, M., Lannfelt, L., **Ingelsson, M.**, Nilsson, L. Analysis of gene expression in brains of a transgenic mouse model for Alzheimer's disease. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Madrid 2006

33. Skoglund, L., Kalimo, H., Herva, R., **Ingelsson, M**., Lannfelt, L., Glaser, A., Viitanen, M. Frontotemporal dementia and parkinsonism: another phenotype of the tau S305S mutation. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Madrid 2006

34. Glaser, A., Giedraitis, V., Kilander, L., Degerman-Gunnarsson, M., Sundelöf, J., Berglund, L., Blom, E., **Ingelsson, M**., Lannfelt, L., Genetic analysis of Alzheimer's disease in the ULSAM cohort. Poster/ Alzheimer's Association International

34. Glaser, A., Giedraitis, V., Kilander, L., Degerman-Gunnarsson, M., Sundelöf, J., Berglund, L., Blom, E., **Ingelsson, M**., Lannfelt, L., Genetic analysis of Alzheimer's disease in the ULSAM cohort. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Madrid 2006

35. Fredriksson, J., Skoglund, L., Bergström, J., Lannfelt, L., **Ingelsson, M**. *In vitro* characterization of tau aggregational properties. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Madrid 2006

36. **Ingelsson, M**., Blom, E., Fukumoto, H., Gårevik, N., Wahlund, L-O., Lannfelt, L., Hyman, B.T., Irizarry, M. Effect of *APOE* genotype on CSF Ab levels in Alzheimer's disease and mild cognitive impairment. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Madrid 2006

37. **Ingelsson, M.**, Fredriksson, J., Irizarry, M., Lannfelt, L., Hyman, B.T. Function and regulation of tau- in vivo and in vitro lessons of FTDP17 mutations. Talk/ Springfield Conference Geneva 2006 (Neurobiol Aging 27S1 (2006) S11)

38. O'Callaghan, P., Li, J-P., Yu, H., Nilsson, LNG., Hyman, BT., Kalimo, H., **Ingelsson, M**., Lindahl, U., Lannfelt, L., Zhang, X. Differential co-localization of heparan sulfate with Aβ40 and Aβ42 deposits in APP-transgenic mice and Alzheimer´s disease. Poster/ AD/PD Salzburg, 2007

39. Giedraitis, V., Irizarry, M., Sundelöf, J., Degerman Gunnarsson, M., Kilander, L., Glaser, A., **Ingelsson, M.,** Hyman, BT., Basun, H., Lannfelt, L. Genetic regulation of Aβ levels in human plasma. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Chicago 2008

40. Nilsson, LNG., Lord, A., Philipson, O., Englund, H., Gumucio Gatics, A., Sehlin, D., Clausen, F., Hillered, L., **Ingelsson, M.,** Gordon, M., Ekholm Pettersson, F., Kalimo, H., Lannfelt, L. Transgenic mice with the Arctic APP mutation as animal models of Alzheimer's disease. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Chicago 2008

41. Englund, H., Sehlin, D., Degerman Gunnarsson, M., Lord, A., Brundin, R-M., **Ingelsson, M.,** Kilander, L., Nilsson, LNG., Ekholm Pettersson, F., Lannfelt, L. Increased levels of CSF Aβ oligomers in AD- combination of techniques allows indirect estimates. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Chicago 2008

42. Nässtrom, T., Wahlberg, T., Karlsson, M., Nikolajeff, F., Lannfelt, L., Bergström, J., **Ingelsson, M.** Oligomeric amorphous species of alpha-synuclein induce toxicity in a cellular model. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Chicago 2008

43. Wahlberg, T., Nässtrom, T., Hedlund, M., Ekholm Pettersson, F., Lannfelt, L., **Ingelsson, M.**, Bergström, J. Development of oligomer-specific alpha-synuclein antibodies. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Chicago 2008

44. Bergström, J., Nässtrom, T., Wahlberg, T., Lannfelt, L., **Ingelsson, M**. Characterization of early events in the alpha-synuclein aggregation pathway. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Chicago 2008

 # 45. Ingelsson, M**., Blom, ES., Zetterberg, H., Fukumoto, H., Hyman, BT., Irizarry, MC:, Blennow, K., Wahlund, L-O., Lannfelt, L. CSF tau levels and APOE*e4* carriership predict the progression of mild cognitive impairment to Alzheimer's disease. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Chicago 2008**

46. Blom, ES, Wang, Y., Hansson, A., Sommer, W., Hyman, BT., Heilig, M., Lannfelt, L., Nilsson, LNG, **Ingelsson, M**. Poster/ Upregulation of genes in the Wnt pathway in tg-ArcSwe mice and Alzheimer's disease brain Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Chicago 2008

47. Bergström, J., Nässtrom, T., Wahlberg, T., Karlsson, M., Nikolajeff, F., Lannfelt, L., **Ingelsson, M**. The Effect of the Lipid Peroxidation Metabolite 4-oxo-2-nonenal on the Structure and Function of Alpha-Synuclein. Poster/ International meeting on alpha-synuclein, Copenhagen 2009

L., **Ingelsson, M**. The Effect of the Lipid Peroxidation Metabolite 4-oxo-2-nonenal on the Structure and Function of Alpha-Synuclein. Poster/ International meeting on alpha-synuclein, Copenhagen 2009

48. Bergström, J., Nässtrom, T., Wahlberg, T., Karlsson, M., Nikolajeff, F., Lannfelt, L., **Ingelsson, M**. Effects of lipid peroxidation metabolites on alpha-synuclein aggregation.Talk/ Society for Neuroscience 39th Annual Meeting, Chicago 2009

49. Nässtrom, T., Wahlberg, T., Karlsson, M., Nikolajeff, F., Lannfelt, L., **Ingelsson, M.**, Bergström, J. Morphological and functional properties of aldehyde-induced alpha-synuclein oligomers. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Honolulu 2010

50. Wahlberg, T., Nässtrom, T., Sahlin, C., Ingvast, S., Karlsson, M., Nikolajeff, F., Ekberg, M., Kasrayan, A., Schell, H., Kahle, P., Lannfelt, L., Bergström, J., **Ingelsson, M.** Seeding of cross linked alpha-synuclein oligomers *in vitro* and *in vivo*. Poster/ Alzheimer's Association International Conference on Alzheimer´s Disease (ICAD) Honolulu 2010

51. Wahlberg, T., Nässtrom, T., Sahlin, C., Ingvast, S., Karlsson, M., Nikolajeff, F., Ekberg, M., Kasrayan, A., Schell, H., Kahle, P., Lannfelt, L., Bergström, J., **Ingelsson, M.** Alpha-synuclein protofibrils can seed fibril formation *in vitro*. Poster/ Society for Neuroscience 40th Annual Meeting, San Diego 2010

52. Welander, H., Bontha, SV., Nässtrom, T., Lannfelt, L., **Ingelsson, M.,** Bergström. J. Alpha-synuclein aggregation is influenced by gelsolin in a cell culture model. Poster/ AD/PD Barcelona, 2011

53. Nässtrom, T., Gonçalves, S., Sahlin, C., Nordström, E., Sundquist, V., Möller, C., Gellerfors, P., Lannfelt, L., Bergström, J., Outeiro, J., **Ingelsson, M.** Treatment with monoclonal antibodies reduces intracellular dimerization/oligomerization of alpha-synuclein in a cell culture model. Poster/ AD/PD Barcelona, 2011

54. **Ingelsson, M.**, Fagerqvist, T., Nässtrom, T., Ihse, E., Lindström, V., Sahlin, C., Tucker, S., Kasrayan, A., Karlsson, M., Nikolajeff, F., Nath, S., Agholme, L., Outeiro, T.F., Hallbeck, M., Lannfelt, L., Bergström, J. Alpha-synuclein oligomers can act as seed in a fibrillization assay but do not cause increased aggregation in living cells. Poster/ AAIC Boston 2013

55. **Ingelsson, M.,** Gustafsson, G., Fonseca, T.L., Lazaro, D., Nordström, E., Ihse, E., Nath, S., Agholme, L., Möller, C., Hallbeck, M., Outeiro, T.F., Lannfelt, L., Bergström, J. Alpha-synuclein oligomers/protofibrils as immunotherapeutic targets in cell models of aggregation and propagation. Talk/ Poster/ Society for Neuroscience 43rd Annual Meeting, San Diego 2013

56. Lindström, V., Sigvardson, J., Kasrayan, A., Lannfelt, L., **Ingelsson, M**., Bergström, J., Erlandsson, A. Alpha-synuclein oligomers are engulfed primarily by astrocytes in a co-culture system with primary neurons and glia. Poster/ Nanonet Training School and Research Conference, Gothenburg 2014

57. **Ingelsson, M.,** Gustafsson, G., Eriksson, F., Nordström, E., Möller, C., Lannfelt, L. Characterization of the cellular uptake of α-synuclein oligomer/protofibril selective antibodies. Poster/ Society for Neuroscience 44th Annual Meeting, Washington 2014

58. Hallbeck, M., Sinha, MS., Ansell, A., Falk, A., Sackmann, C., Severinsson, E., **Ingelsson, M.,** Bergström, J., Marcusson, J. Mechanisms for neuron-to-neuron transmission of neurodegenerative proteins. Poster / Society for Neuroscience 44th Annual Meeting, Washington 2014

59. Bergström, J., Almandoz-Gil, L., Sigvardsson, J., Lannfelt, L., **Ingelsson, M.** Characterization of surface-exposed epitopes of *in vitro* and *in vivo* formed alpha-synuclein aggregates. Talk (Bergström) / Society for Neuroscience 44th Annual Meeting, Washington 2014

Characterization of surface-exposed epitopes of *in vitro* and *in vivo* formed alpha-synuclein aggregates. Talk (Bergström) / Society for Neuroscience 44th Annual Meeting, Washington 2014

60. Gustafsson, G., Eriksson, F., Möller, C., Outeiro, T.F., Lannfelt, L., Bergstrom, J., **Ingelsson, M.** Characterisation of the cellular uptake of alpha-synuclein oligomer/protofibril selective antibodies. Poster / AD/PD Nice 2015

61. Eriksson, F., Ramberg, V., Sigvardson, J., Kasrayan, A., **Ingelsson, M.,** Kahle, P., Lannfelt, L., Osswald, G., Möller, C., Nordström, E. Alpha-synuclein protofibril-selective antibody prevents motor related death in alpha-synuclein A30P tg mice. Poster / AD/PD Nice 2015

62. Almandoz-Gil, L., Sigvardsson, J., Lannfelt, L., **Ingelsson, M.,** Bergström, J. Epitope mapping of aggregated forms of alpha-synuclein. Poster / AD/PD Nice 2015

63. Lindström, V., Gustafsson, G., Sigvardsson, J., Kasrayan, A., Lannfelt, L., **Ingelsson, M.**, Bergström, J., Erlandsson, A. Extensive uptake of alpha-synuclein oligomers in primary astrocytes – a central pathological mechanism in Parkinson's disease? Poster / AD/PD Nice 2015

Thesis

Ingelsson, M: "Molecular Aspects of Tau Proteins in Alzheimer's Disease and Frontotemporal Dementia". Karolinska Institute, Stockholm, Sweden, defended on 09/28/2001. Faculty Opponent: Dr. Simon Lovestone, King's College, London, UK.

Narrative Report

Being a specialist in Geriatric Medicine at Uppsala University Hospital and an Associate Professor of Experimental Geriatrics at Uppsala University, Martin Ingelsson is dedicated to the care of patients with various neurodegenerative disorders and to the advancement of novel therapies and diagnostic methods for this patient group. His current position allows him to spend approximately 60% of his time in the laboratory doing translational molecular research, 20% in the Memory Disorder Unit seeing patients and 20% teaching clinical skills to medical students as well as supervising his PhD students in their respective research projects.

Among his achievements, Dr. Ingelsson has published more than 70 original papers, reviews and book chapters. He has studied amyloid-beta, tau and alpha-synuclein, proteins involved in the pathogeneses of Alzheimer's disease and Parkinson's disease. He has characterized the presence of soluble and insoluble forms of aggregated amyloid-beta and alpha-synuclein and described the regulation of the corresponding genes in brains from patients with the respective disorders. Different cell and animal models are now being used to explore the aggregation behavior of these proteins, with the focus of understanding neurotoxic mechanisms. Among other studies, seeding and propagation properties of amyloid-beta are currently being investigated in a collaborative study with Dr. Stanley Prusiner. Moreover, monoclonal antibodies that are selective against toxic forms of alpha-synuclein have been generated and are now being evaluated as tools for diagnostic and immunotherapeutic applications. In a recently concluded study, Dr. Ingelsson was able to show that peripheral treatment with an oligomer-selective antibody against alpha-synuclein could lower the levels of toxic alpha-sýnuclein in the CNS of a transgenic Parkinson's disease mouse model.

Apart from investigating and treating patients with different cognitive and motor symptoms, Dr. Ingelsson has been the PI of several clinical trials, aimed at exploring the use of monoclonal antibodies as disease-modifying treatment in Alzheimer's disease. In an ongoing trial, the effect of an antibody that was developed in the Uppsala laboratory and which is selectively targeting toxic protofibrillar forms of amyloid-beta, is being evaluated in a phase II b clinical trial on Alzheimer patients.

In order to improve the scientific understanding among medical students, Dr. Ingelsson has organized a laboratory course that has been integrated in the curriculum. In addition, he has served as a well appreciated mentor during the clinical training periods for medical students in their fourth year.

Taken together, Dr. Ingelsson has been able to successfully integrate his preclinical and clinical activities in a translational setting with the clear aim of utilizing research results from the laboratory to increase our understanding of these devastating diseases.

Taken together, Dr. Ingelsson has been able to successfully integrate his preclinical and clinical activities in a translational setting with the clear aim of utilizing research results from the laboratory to increase our understanding of these devastating diseases. Such novel knowledge will be essential for the development of the next generation of disease-modifying drugs against these disorders.